<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">57646</article-id><article-id pub-id-type="doi">10.7554/eLife.57646</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Thresholds for post-rebound SHIV control after CCR5 gene-edited autologous hematopoietic cell transplantation</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-182270"><name><surname>Cardozo-Ojeda</surname><given-names>E Fabian</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8690-9896</contrib-id><email>ecojeda@fredhutch.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-184915"><name><surname>Duke</surname><given-names>Elizabeth R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-184916"><name><surname>Peterson</surname><given-names>Christopher W</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-63349"><name><surname>Reeves</surname><given-names>Daniel B</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5684-9538</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-184917"><name><surname>Mayer</surname><given-names>Bryan T</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-184918"><name><surname>Kiem</surname><given-names>Hans-Peter</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-165403"><name><surname>Schiffer</surname><given-names>Joshua T</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2598-1621</contrib-id><email>jschiffe@fredhutch.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Vaccine and Infectious Disease Division, University of Washington</institution><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Medicine, University of Washington</institution><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Clinical Research Division, Fred Hutchinson Cancer Research Center</institution><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center</institution><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Department of Pathology, University of Washington</institution><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Davenport</surname><given-names>Miles P</given-names></name><role>Reviewing Editor</role><aff><institution>University of New South Wales</institution><country>Australia</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Walczak</surname><given-names>Aleksandra M</given-names></name><role>Senior Editor</role><aff><institution>École Normale Supérieure</institution><country>France</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>12</day><month>01</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e57646</elocation-id><history><date date-type="received" iso-8601-date="2020-04-07"><day>07</day><month>04</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-12-27"><day>27</day><month>12</month><year>2020</year></date></history><permissions><copyright-statement>© 2021, Cardozo-Ojeda et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Cardozo-Ojeda et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-57646-v1.pdf"/><abstract><p>Autologous, CCR5 gene-edited hematopoietic stem and progenitor cell (HSPC) transplantation is a promising strategy for achieving HIV remission. However, only a fraction of HSPCs can be edited ex vivo to provide protection against infection. To project the thresholds of CCR5-edition necessary for HIV remission, we developed a mathematical model that recapitulates blood T cell reconstitution and plasma simian-HIV (SHIV) dynamics from SHIV-1157ipd3N4-infected pig-tailed macaques that underwent autologous transplantation with CCR5 gene editing. The model predicts that viral control can be obtained following analytical treatment interruption (ATI) when: (1) transplanted HSPCs are at least fivefold higher than residual endogenous HSPCs after total body irradiation and (2) the fraction of protected HSPCs in the transplant achieves a threshold (76–94%) sufficient to overcome transplantation-dependent loss of SHIV immunity. Under these conditions, if ATI is withheld until transplanted gene-modified cells engraft and reconstitute to a steady state, spontaneous viral control is projected to occur.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>mathematical modeling</kwd><kwd>HIV cure</kwd><kwd>pigtailed macaque</kwd><kwd>hematopoietic ΔCCR5 stem cells</kwd><kwd>autologous transplantation</kwd><kwd>nonlinear mixed-effects</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>UM1 AI126623</award-id><principal-award-recipient><name><surname>Cardozo-Ojeda</surname><given-names>E Fabian</given-names></name><name><surname>Peterson</surname><given-names>Christopher W</given-names></name><name><surname>Kiem</surname><given-names>Hans-Peter</given-names></name><name><surname>Schiffer</surname><given-names>Joshua T</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>R01 AI150500</award-id><principal-award-recipient><name><surname>Cardozo-Ojeda</surname><given-names>E Fabian</given-names></name><name><surname>Schiffer</surname><given-names>Joshua T</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006108</institution-id><institution>National Center for Advancing Translational Sciences</institution></institution-wrap></funding-source><award-id>KL2 TR002317</award-id><principal-award-recipient><name><surname>Duke</surname><given-names>Elizabeth R</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007813</institution-id><institution>Center for AIDS Research</institution></institution-wrap></funding-source><award-id>New Investigator Award P30 AI027757</award-id><principal-award-recipient><name><surname>Reeves</surname><given-names>Daniel B</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001906</institution-id><institution>Washington Research Foundation</institution></institution-wrap></funding-source><award-id>Postdoctoral Fellowship</award-id><principal-award-recipient><name><surname>Reeves</surname><given-names>Daniel B</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P51 OD010425</award-id><principal-award-recipient><name><surname>Kiem</surname><given-names>Hans-Peter</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Mathematical models reveal the conditions required for long-term HIV remission using autologous transplantation of hematopoietic stem cells.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The major obstacle to HIV-1 eradication is a latent reservoir of long-lived, infected cells (<xref ref-type="bibr" rid="bib12">Chun et al., 1997</xref>; <xref ref-type="bibr" rid="bib11">Chun et al., 1995</xref>; <xref ref-type="bibr" rid="bib24">Finzi et al., 1997</xref>). Cure strategies aim to eliminate all infected cells or permanently prevent viral reactivation from latency. The only two known cases of HIV cure, the ‘Berlin Patient’ and ‘London Patient’, resulted from allogeneic hematopoietic stem cell (HSC) transplant with homozygous CCR5Δ32 donor cells (<xref ref-type="bibr" rid="bib1">Allers et al., 2011</xref>; <xref ref-type="bibr" rid="bib36">Hütter et al., 2009</xref>; <xref ref-type="bibr" rid="bib27">Gupta et al., 2019</xref>; <xref ref-type="bibr" rid="bib28">Gupta et al., 2020</xref>), a mutation that makes cells resistant to CCR5-tropic HIV-1. The Berlin Patient was diagnosed with HIV in 1995 and received total body irradiation and allo-HSC transplantation for the treatment of his acute myeloid leukemia in 2007 and 2008. On the day of his first transplantation, antiretroviral therapy (ART) was interrupted, and HIV viremia never returned (<xref ref-type="bibr" rid="bib1">Allers et al., 2011</xref>; <xref ref-type="bibr" rid="bib36">Hütter et al., 2009</xref>; <xref ref-type="bibr" rid="bib60">Peterson and Kiem, 2019</xref>). In 2019, an HIV-1 remission for more than 18 months was reported in the London Patient as part of the IciSTEM cohort (<xref ref-type="bibr" rid="bib27">Gupta et al., 2019</xref>). The London Patient underwent one allo-HSC transplantation for treatment of Hodgkin Lymphoma in 2016, but with a less aggressive conditioning compared to the Berlin patient without irradiation (<xref ref-type="bibr" rid="bib27">Gupta et al., 2019</xref>). This individual stopped ART 17 months after transplantation and as of March, 2020 his viremia remains suppressed, representing a possible case of HIV-1 cure (<xref ref-type="bibr" rid="bib28">Gupta et al., 2020</xref>). The success of the allo-HSC transplantation is likely multifactorial—in part attributable to HIV resistance of the transplanted cells, the conditioning regimen that facilitates engraftment and eliminates infected cells, graft-versus-host effect against residual infected cells, and immunosuppressive therapies for graft-versus-host disease (<xref ref-type="bibr" rid="bib32">Henrich et al., 2016</xref>; <xref ref-type="bibr" rid="bib31">Henrich et al., 2014</xref>; <xref ref-type="bibr" rid="bib30">Henrich et al., 2013</xref>; <xref ref-type="bibr" rid="bib66">Salgado et al., 2018</xref>).</p><p>We are interested in recapitulating this method of cure but with reduced toxicity. Specifically, we are investigating the use of autologous transplantation following ex vivo inactivation of the CCR5 gene with gene-editing (<xref ref-type="bibr" rid="bib79">Tebas, 2014</xref>; <xref ref-type="bibr" rid="bib57">Peterson et al., 2016</xref>). This procedure is safe and feasible in pigtail macaques infected with simian-HIV (SHIV) (<xref ref-type="bibr" rid="bib57">Peterson et al., 2016</xref>; <xref ref-type="bibr" rid="bib58">Peterson et al., 2017</xref>; <xref ref-type="bibr" rid="bib59">Peterson et al., 2018</xref>) and is currently being investigated in a Phase I clinical trial in suppressed, HIV-1-infected humans (NCT02500849). Also, this approach is more broadly applicable because an allogeneic CCR5-negative donor is not needed. However, current data suggests that protocols do not achieve sufficient fractions of genetically modified HIV-resistant hematopoietic stem and progenitor cells (HSPCs). In contrast, in allogeneic transplant, nearly 100% of circulating immune cells after engraftment consist of donor-derived CCR5Δ32 cells. This leads to a key question: what threshold percentage of CCR5-edited, autologous HSPCs is necessary for the cure/long-term remission observed in the Berlin and London patients?</p><p>To answer this question, we developed a mathematical model that predicts the minimum threshold of gene-modified cells necessary for functional cure. First, we modeled the kinetics of CD4<sup>+</sup>CCR5<sup>+</sup>, CD4<sup>+</sup> CCR5<sup>-</sup>, and CD8<sup>+</sup> T cell reconstitution after autologous transplantation. Then, we modeled SHIV kinetics during acute infection and rebound following ATI to identify the degree of loss of anti-HIV cytolytic immunity following transplantation as presented before but including some additional data (<xref ref-type="bibr" rid="bib58">Peterson et al., 2017</xref>; <xref ref-type="bibr" rid="bib64">Reeves et al., 2017</xref>). Finally, we applied our models to predict the proportion of gene-modified cells, the dose of these cells relative to the intensity of the preparative conditioning regimen (total body irradiation, TBI), and the levels of SHIV-specific immunity required to maintain virus remission following ATI. Results from this three-part modeling approach support strategies that (1) increase stem cell dose, (2) enhance potency of conditioning regimen to reduce the number of endogenous HSPCs that compete with transplanted CCR5-edited HSPCs, (3) increase the fraction of gene-modified SHIV-resistant cells, (4) extend periods between HSPC transplantation and ATI with tracking of CCR5- cell recovery and/or (5) augment anti-HIV immunity to achieve sustained HIV remission.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Study design and mathematical modeling</title><p>We analyzed data from 22 juvenile pig-tailed macaques that were intravenously challenged with 9500 TCID50 SHIV1157ipd3N4 (SHIV-C) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). After 6 months of infection, the macaques received combination ART that included tenofovir (PMPA), emtricitabine (FTC), and raltegravir (RAL). When on ART, 17/22 received total body irradiation (TBI) followed by the transplantation of autologous HSPCs with (n = 12) or without (n = 5) CCR5 gene editing (ΔCCR5 and WT groups, respectively). A control group (n = 5) did not receive TBI or HSPC transplantation. 14 of the animals underwent ATI approximately 1 year after ART initiation. The remaining eight animals were necropsied at an earlier time relative to the other animals’ ATI (see Materials and methods for details).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Study design and mathematical modeling.</title><p>(<bold>A</bold>) Twenty-two pig-tailed macaques were infected with SHIV and suppressed with ART. Next, 17/22 underwent hematopoietic stem and progenitor cell (HSPC) transplantation following myeloablative conditioning (TBI), including 12 animals that received CCR5-edited products and five that received non-edited products (ΔCCR5 and WT groups, respectively). A control group (n = 5) did not receive TBI or HSPC transplantation. Fourteen animals underwent ATI approximately 1 year after ART initiation, while the remaining eight animals were necropsied prior to ATI (see Materials and methods for details). (<bold>B</bold>) We first developed mathematical models for T cell dynamics and reconstitution following transplant and before ATI (purple), assuming that low viral loads on ART do not affect cell dynamics. After validation of that model, we introduced viral dynamics and fit those to the T cell, primary infection, and viral rebound dynamics from the animals pre- and post-ATI (blue).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57646-fig1-v1.tif"/></fig><p>To analyze the data and estimate thresholds for viral control under this approach, we used ordinary differential equation models. We performed multi-stage modeling (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). First, we modeled the kinetics of CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets after autologous HSPC infusion following transplant and before ATI, assuming that ART suppression decouples SHIV-dynamics from cellular dynamics. After validation of the first-stage model, we introduced a second-stage of modeling to (1) explain virus and T cell kinetics during primary infection and ATI and to (2) identify the degree of loss of anti-HIV cytolytic immunity due to the preparative conditioning. Then, we used the final validated model to project SHIV kinetics assuming different transplantation conditions.</p></sec><sec id="s2-2"><title>CD4<sup>+</sup>CCR5<sup>+</sup> and CD8<sup>+</sup> T cells recover more rapidly than CD4<sup>+</sup>CCR5<sup>-</sup> T cells after HSPC transplantation</title><p>We analyzed the kinetics of peripheral blood CD4<sup>+</sup>CCR5<sup>+</sup> and CD4<sup>+</sup>CCR5<sup>-</sup> T cells, and total, T<sub>naive</sub>, T<sub>CM</sub>, and T<sub>EM</sub> CD8<sup>+</sup> T cells in macaques after HSPC transplantation.</p><p>In untransplanted controls, levels of CD4<sup>+</sup> and CD8<sup>+</sup> T cells oscillated around a persistent set point (blue data-points in <xref ref-type="fig" rid="fig2">Figure 2A</xref>). Also, CD4<sup>+</sup> CCR5<sup>+</sup> T cell levels were ~100 cells/μL and were uniformly lower than the CD4<sup>+</sup>CCR5<sup>-</sup> T counts (each ~1000 cells/μL) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Finally, total CD8<sup>+</sup> T cell levels in the control group were ~1400 cells/μL with a greater contribution from T<sub>EM</sub> (73%) than T<sub>N</sub>+T<sub>CM</sub> (27%) (based on median values, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Post-transplantation, pre-ATI CD4<sup>+</sup> and CD8<sup>+</sup> T cell dynamics.</title><p>(<bold>A</bold>) Empirical data for peripheral CD4<sup>+</sup> CCR5<sup>+</sup> (top row), CD4<sup>+</sup>CCR5<sup>-</sup> (middle row), and CD8<sup>+</sup> T cell counts (bottom row) for control (blue), wild-type (red), and ΔCCR5 (green) transplantation groups. Each data point shape and color is a different animal sampled over time. (<bold>B</bold>) Distributions of blood CD4<sup>+</sup> and CD8<sup>+</sup> T cell counts for weeks 0, 10, and 25 after transplantation (p-values calculated with pairwise Mann-Whitney test with Bonferroni correction comparing control group with transplant groups. <sup>*</sup>p&lt;0.05, <sup>**</sup>p&lt;0.01 and <sup>***</sup>p&lt;0.001). (<bold>C</bold>) Expansion-rate estimates of CD4<sup>+</sup>CCR5<sup>+</sup>, CD4<sup>+</sup>CCR5<sup>-</sup>, and CD8<sup>+</sup> T cells (p-values calculated with paired Mann-Whitney test with Bonferroni correction comparing expansion rates of CD4<sup>+</sup>CCR5<sup>-</sup> with CD4<sup>+</sup>CCR5<sup>+</sup> and CD8<sup>+</sup> in transplant groups. <sup>**</sup>p&lt;0.01 for both). Colors for boxplots in B and C are matched to A (blue: control, red: wild-type-transplantation, and green: ΔCCR5-transplantation groups).</p><p><supplementary-material id="fig2scode1"><label>Figure 2—source code 1.</label><caption><title>R code for plots and tests in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-57646-fig2-code1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Complete data set of blood T cell counts for <xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-57646-fig2-data1-v1.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57646-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>CD4<sup>+</sup> and CD8<sup>+</sup> T cell levels pre-ATI in control group (n = 5) at times relative to post-transplantation in WT and ΔCCR5 transplant groups.</title><p>Range of blood (<bold>A</bold>) CD4<sup>+</sup> and (<bold>B</bold>) CD8<sup>+</sup> T cell counts using all data points for the period before ATI in control animals (p-value calculated with a paired t-test for averaged measurements from a time relative to infusion in transplanted animals and before ATI).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57646-fig2-figsupp1-v1.tif"/></fig></fig-group><p>In the transplant groups, post-TBI levels of CD4<sup>+</sup>CCR5<sup>+</sup>, CD4<sup>+</sup>CCR5<sup>-</sup>, and CD8<sup>+</sup> T cells were significantly lower than in the control group but expanded at different rates during the following weeks (<xref ref-type="fig" rid="fig2">Figure 2A–C</xref>). The levels of CD4<sup>+</sup>CCR5<sup>+</sup> T cells started at 1–10 cells/μL and reconstituted to levels similar to the control group over 5–10 weeks (<xref ref-type="fig" rid="fig2">Figure 2A–B</xref>). CD4<sup>+</sup>CCR5<sup>-</sup> T cells remained at higher levels (~100 cells/μL) than CD4<sup>+</sup>CCR5<sup>+</sup> T cells after TBI but expanded more slowly and did not reach the values of the control group after 25 weeks (<xref ref-type="fig" rid="fig2">Figure 2A–B</xref>). The CD4<sup>+</sup>CCR5<sup>+</sup> T cell compartment expanded eightfold more rapidly than the CD4<sup>+</sup>CCR5<sup>-</sup> compartment (p=0.008, paired Mann-Whitney test, <xref ref-type="fig" rid="fig2">Figure 2C</xref>). CD8<sup>+</sup> T cells decreased to levels between 10 and 100 cells/μL after TBI but recovered to levels just below the control group in 5 weeks (<xref ref-type="fig" rid="fig2">Figure 2A–B</xref>); CD8<sup>+</sup> T cells recovered as rapidly as the CD4<sup>+</sup>CCR5<sup>+</sup> population (<xref ref-type="fig" rid="fig2">Figure 2C</xref>).</p><p>Overall, these results show that after transplantation CD4<sup>+</sup>CCR5<sup>+</sup> and CD8<sup>+</sup> T cells recover faster than CD4<sup>+</sup>CCR5<sup>-</sup> cells. This suggests that each cell subset may have different and/or complementary mechanisms that drive their expansion. To explore these mechanisms, we analyzed the data with a mechanistic mathematical model of cellular dynamics.</p></sec><sec id="s2-3"><title>Lymphopenia-induced proliferation drives early CD4<sup>+</sup>CCR5<sup>+</sup> and CD8<sup>+</sup> T cell reconstitution after HSPC transplantation</title><p>To identify the main drivers of T cell reconstitution after transplant, we developed a mathematical model that considered plausible mechanisms underlying reconstitution of distinct T cell subsets following autologous transplantation (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). We assumed that T cell reconstitution may have two main drivers: (1) lymphopenia-induced proliferation of mature cells that persist through myeloablative TBI (<xref ref-type="bibr" rid="bib37">Jameson, 2002</xref>; <xref ref-type="bibr" rid="bib69">Schluns et al., 2002</xref>; <xref ref-type="bibr" rid="bib68">Schluns et al., 2000</xref>; <xref ref-type="bibr" rid="bib25">Goldrath et al., 2004</xref>; <xref ref-type="bibr" rid="bib80">Voehringer et al., 2008</xref>) and (2) differentiation from naive cells from progenitors in the thymus (from transplanted CD34<sup>+</sup> HSPCs (<xref ref-type="bibr" rid="bib20">Douek et al., 2000</xref>; <xref ref-type="bibr" rid="bib19">Douek et al., 1998</xref>) or residual endogenous CD34<sup>+</sup> HSPCs that persist following TBI) and further differentiation to an activated effector state (<xref ref-type="bibr" rid="bib80">Voehringer et al., 2008</xref>; <xref ref-type="bibr" rid="bib2">Bender et al., 1999</xref>; <xref ref-type="bibr" rid="bib39">Kieper and Jameson, 1999</xref>; <xref ref-type="bibr" rid="bib67">Sallusto et al., 2004</xref>; <xref ref-type="bibr" rid="bib44">Le Saout et al., 2008</xref>; <xref ref-type="bibr" rid="bib72">Sprent and Surh, 2011</xref>). We also assumed the infused product dose <inline-formula><mml:math id="inf1"><mml:mi>D</mml:mi></mml:math></inline-formula> contains a fraction <inline-formula><mml:math id="inf2"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> of transplanted, gene-edited HSPCs that do not express CCR5 (see <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref> for individual values of <inline-formula><mml:math id="inf3"><mml:mrow><mml:mo> </mml:mo><mml:mi>D</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf4"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>). Thus, in our model, ΔCCR5-gene-modified CD4<sup>+</sup> T cells differentiating from these modified HSPCs are a subset of the total CD4<sup>+</sup>CCR5<sup>-</sup> cell compartment (<xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Mathematical model of T cell reconstitution after hematopoietic stem and progenitor cell (HSPC) transplantation.</title><p>(<bold>A</bold>) Schematics of the model. Each circle represents a cell compartment: T represents the HSPCs from the transplant; P, the progenitor cells in bone marrow (BM) and thymus; S and N, CD4<sup>+</sup>CCR5<sup>+</sup> and CD4<sup>+</sup>CCR5<sup>-</sup> T cells, respectively; T<sub>p</sub>, the protected (ΔCCR5), gene-modified cells from transplant; P<sub>p</sub>, protected (ΔCCR5) progenitor cells in BM/thymus; N<sub>p1</sub> and N<sub>p2</sub> the protected (ΔCCR5) CD4<sup>+</sup> T cells; M the CD8<sup>+</sup> T cells with naive and central memory phenotype and E CD8<sup>+</sup> T cells with effector memory phenotype. The initial fraction of protected cells in the product is represented by the parameter f<sub>p</sub>. Gray panels represent mature blood CD4<sup>+</sup> and CD8<sup>+</sup> T cells, and the green panel all ΔCCR5 cells in the model. Red, dashed arrows represent discarded terms after model selection and validation (see text for details). (<bold>B</bold>) Model predictions using the maximum likelihood estimation of the population parameters (solid black lines) for all blood T cell subsets before ATI for all animals in the transplant groups using model with ΔAIC = 0 (<xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source datas 2</xref>–<xref ref-type="supplementary-material" rid="fig3sdata3">3</xref>). Each gray line is one animal. (<bold>C</bold>) Model predictions of the total concentration of CD4<sup>+</sup>CCR5<sup>-</sup> T cells generated by CCR5 downregulation (dashed line) or thymic export (solid line), and of the total concentration of CD4<sup>+</sup>CCR5<sup>+</sup> T cells generated by proliferation (solid line) or by upregulation of CCR5 (dashed line) over time using the maximum likelihood estimation of the population parameters.</p><p><supplementary-material id="fig3scode1"><label>Figure 3—source code 1.</label><caption><title>Best model file for T cell reconstitution in Monolix format.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-57646-fig3-code1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3scode2"><label>Figure 3—source code 2.</label><caption><title>R code for plots in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-57646-fig3-code2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Values of the fraction of protected cells in transplant product <inline-formula><mml:math id="inf5"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, dose or number of hematopoietic stem and progenitor cell (HSPCs) in transplant product <inline-formula><mml:math id="inf6"><mml:mi>D</mml:mi></mml:math></inline-formula> and time of transplantation <inline-formula><mml:math id="inf7"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mi>x</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> of each animal for model fitting and projections.</title><p>We assumed animal weight of 5 Kg.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-57646-fig3-data1-v1.docx"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Competing models for fitting T cell reconstitution with respective AIC values.</title><p>Best fit in bold-red (lowest AIC). The AIC values presented for each statistical assumption is the lowest of 10 runs of the SAEM algorithm with different randomly selected initial guesses.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-57646-fig3-data2-v1.docx"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Population parameter estimates for the best fits of the model in <xref ref-type="disp-formula" rid="equ2">Equation 2</xref> in the main text (lowest AIC in <xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref>) to the T cell reconstitution dynamics.</title><p>RSE: relative standard error. Empty fields represent a standard deviation of random effects, <inline-formula><mml:math id="inf8"><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mi>ψ</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, fixed to zero. Values of <inline-formula><mml:math id="inf9"><mml:mover accent="true"><mml:mi>ψ</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:math></inline-formula> for <inline-formula><mml:math id="inf10"><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>S</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>M</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf11"><mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> shown here are in log<sub>10</sub> cell counts/μL assuming a blood volume of of 3 × 10<sup>5</sup> μL (calculated assuming blood:weight ratio of 60 mL/kg and body weight of 5 kg). Red values represent an RSE greater than 100% implying that the number of data points may not be enough to estimate the respective parameter.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-57646-fig3-data3-v1.docx"/></supplementary-material></p><p><supplementary-material id="fig3sdata4"><label>Figure 3—source data 4.</label><caption><title>Individual parameter estimates for the best fits of the model in <xref ref-type="disp-formula" rid="equ2">Equation 2</xref> in the main text (lowest AIC in <xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref>) to the T cell reconstitution dynamics.</title><p>Values obtained for <inline-formula><mml:math id="inf12"><mml:mrow><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>S</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>M</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf13"><mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> shown here are in log<sub>10</sub> cell counts/μL assuming a blood volume of of 3 × 10<sup>5</sup> μL (calculated assuming blood:weight ratio of 60 mL/kg and body weight of 5 kg). Initial values for the control group where obtained assuming steady state.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-57646-fig3-data4-v1.docx"/></supplementary-material></p><p><supplementary-material id="fig3sdata5"><label>Figure 3—source data 5.</label><caption><title>Population parameter estimates for the best fits used in the R code for <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-57646-fig3-data5-v1.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57646-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Individual fits of the best model to the blood T cell observations pre-ATI in control group from a time relative to post-transplantation in transplant groups.</title><p>Empirical data for peripheral T cell subset counts (blue data points) and best fits of the model (black lines) in <xref ref-type="disp-formula" rid="equ2">Equation 2</xref> in the main text to all blood T cell subsets before/after ATI for the control group. Each row is one animal (ID in the leftmost graph per row). Each datapoint shape and color is a different animal sampled over time and is maintained throughout.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57646-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Individual fits of the best model to the blood T cell observations post-transplantation, pre-ATI for the wild-type-transplant group.</title><p>Empirical data for peripheral T cell subset counts and plasma viral load (red data points) and best fits of the model (black lines) in <xref ref-type="disp-formula" rid="equ2">Equation 2</xref> in the main text to all blood T cell subsets before ATI for the wild-type-transplant group. Each row is one animal (ID in the leftmost graph per row).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57646-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Individual fits of the best model to the blood T cell observations post-transplantation, pre-ATI for the ΔCCR5-transplant group.</title><p>Empirical data for peripheral T cell subset counts and plasma viral load (green data points) and best fits of the model (black lines) in <xref ref-type="disp-formula" rid="equ2">Equation 2</xref> in the main text to all blood T cell subsets before ATI for the ΔCCR5-transplant group. Each row is one animal (ID in the leftmost graph per row).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57646-fig3-figsupp3-v1.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Predictions of the best model for the contributors to cell expansion in CD8+ TEM cells in animals from the transplant groups.</title><p>Solid line represents the total number of cells that proliferate over time <inline-formula><mml:math id="inf14"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>r</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>e</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mi>S</mml:mi><mml:mo>+</mml:mo><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mi>e</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>E</mml:mi></mml:mrow></mml:math></inline-formula>. Dashed lines indicate the number of exogenous cells differentiated from T<sub>naive</sub> and T<sub>CM</sub> (<inline-formula><mml:math id="inf15"><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula>) over time using the maximum likelihood estimation of the population parameters.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57646-fig3-figsupp4-v1.tif"/></fig></fig-group><p>We built 24 versions of the model by assuming that one or multiple mechanisms are absent, or by assuming certain mechanisms have equivalent or differing kinetics (<xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref>). Using model selection theory, we identified the most parsimonious model that reproduced the data (schematic in <xref ref-type="fig" rid="fig3">Figure 3A</xref> without red-dashed lines). The best model predictions for each cell subset using maximum likelihood estimates of the population parameters (<xref ref-type="supplementary-material" rid="fig3sdata3">Figure 3—source data 3</xref>) are presented in <xref ref-type="fig" rid="fig3">Figure 3B</xref>. Individual fits are visualized in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>–<xref ref-type="fig" rid="fig3s3">3</xref> and parameter estimates are collected in <xref ref-type="supplementary-material" rid="fig3sdata4">Figure 3—source data 4</xref>.</p><p>Model selection illuminated several likely biological phenomena: (1) CD4<sup>+</sup>CCR5<sup>+</sup> T cell reconstitution after transplant is determined by cell proliferation and to a minor degree by upregulation of CCR5 (<xref ref-type="fig" rid="fig3">Figure 3C</xref>); (2) CD4<sup>+</sup>CCR5<sup>-</sup> T cell expansion is driven primarily by new naive cells from the thymus and to a lesser extent by CCR5 downregulation (<xref ref-type="fig" rid="fig3">Figure 3C</xref>); and (3) thymic export is not significantly different for CD4<sup>+</sup> or CD8<sup>+</sup> T cells (<xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref>). However, model selection could not distinguish between the two models where ΔCCR5-gene-modified CD4<sup>+</sup> T cells have the kinetics of both non-modified CD4<sup>+</sup>CCR5<sup>+</sup> and CD4<sup>+</sup>CCR5<sup>-</sup> versus only the kinetics of non-modified CD4<sup>+</sup>CCR5<sup>-</sup> (i.e. having compartment <italic>N<sub>p</sub></italic><sub>2</sub> or not in <xref ref-type="fig" rid="fig3">Figure 3A</xref>). Regardless, these two best models were identical in all other respects (<xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source datas 2</xref> and <xref ref-type="supplementary-material" rid="fig3sdata3">3</xref>).</p><p>This first-stage modeling suggested additional testable biological predictions. First, the estimated CD4<sup>+</sup>CCR5<sup>+</sup> T cell proliferation rate (~0.1/day) far exceeds the estimated CCR5 upregulation (~0.004/day) and thymic export rates (~0.002/day). Therefore, 1 month after transplantation, the total concentration of CD4<sup>+</sup>CCR5<sup>+</sup> T cells generated by proliferation is predicted to be 40-fold higher than the concentration generated by upregulation of CCR5 (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Second, the CD8<sup>+</sup> T<sub>EM</sub> cells comprise the majority of the total CD8<sup>+</sup> T cell compartment (<xref ref-type="fig" rid="fig3">Figure 3B</xref>) with a proliferation rate up to 10-fold higher than the CD8<sup>+</sup> T<sub>CM</sub> cell differentiation rate (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>). In this way, CD8<sup>+</sup> T cells follow a similar pattern to CD4<sup>+</sup>CCR5<sup>+</sup> T cells (<xref ref-type="fig" rid="fig3">Figure 3B</xref>).</p><p>In summary, following autologous HSPC transplant: (1) thymic export and downregulation of CCR5 drive a modest expansion of CD4<sup>+</sup>CCR5<sup>-</sup> T cells, whereas (2) rapid lymphopenia-induced proliferation after TBI is the main driver for CD4<sup>+</sup>CCR5<sup>+</sup> and CD8<sup>+</sup> T cell expansion, which are derived from both the transplanted HSPC product and residual endogenous cells that persisted through the myeloablative conditioning regimen.</p></sec><sec id="s2-4"><title>Plasma virus and blood CD4<sup>+</sup>CCR5<sup>+</sup> dynamics are heterogenous among transplanted, SHIV-infected animals</title><p>To build a mathematical model for the virus and T cell dynamics, we analyzed plasma viral load kinetics and CD4<sup>+</sup>CCR5<sup>+</sup>/CCR5<sup>-</sup> T cell subset dynamics after ATI with respect to kinetics pre-ART (<xref ref-type="bibr" rid="bib58">Peterson et al., 2017</xref>; <xref ref-type="bibr" rid="bib64">Reeves et al., 2017</xref>). <xref ref-type="fig" rid="fig4">Figure 4A</xref> presents the plasma viral loads and the blood CD4<sup>+</sup>CCR5<sup>+</sup> and CD4<sup>+</sup>CCR5<sup>-</sup> T cell kinetics before and after transplantation in the three groups.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Plasma viral load and CD4<sup>+</sup> T cell kinetics after ATI.</title><p>(<bold>A</bold>) Empirical data for viral load (top row) and peripheral T cell counts (middle and bottom rows) for control (blue), wild-type (red) and ΔCCR5 (green) transplantation groups. Each data point shape and color represent a different animal sampled over time. (<bold>B</bold>) Distributions of the ratio at ATI vs pre-ART of final, nadir, and median viral load. Dotted horizontal lines represent a ratio equal to one (or no difference between ATI vs nadir).</p><p><supplementary-material id="fig4scode1"><label>Figure 4—source code 1.</label><caption><title>R code for plots and test in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-57646-fig4-code1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Complete data set of blood T cell counts and viral load for <xref ref-type="fig" rid="fig4">Figures 4</xref> and <xref ref-type="fig" rid="fig5">5</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-57646-fig4-data1-v1.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57646-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Blood CD4<sup>+</sup>CCR5<sup>+</sup> and CD4<sup>+</sup>CCR5<sup>-</sup> T cell kinetics post-ATI.</title><p>(<bold>A</bold>) Distribution of the CD4<sup>+</sup>CCR5<sup>+</sup> T-cell nadir post-ATI normalized relative to the CD4<sup>+</sup>CCR5<sup>+</sup> concentration at ATI. (<bold>B</bold>) Distribution of the CD4<sup>+</sup>CCR5<sup>-</sup> T-cell nadir post-ATI normalized relative to the CD4<sup>+</sup>CCR5<sup>-</sup> concentration at ATI.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57646-fig4-figsupp1-v1.tif"/></fig></fig-group><p>We calculated the ratio of the viral load at necropsy versus at initiation of ART (<xref ref-type="fig" rid="fig4">Figure 4B</xref>) and the ratio of the nadir and median viral load after ATI versus pre-ART (<xref ref-type="fig" rid="fig4">Figure 4C–D</xref>). In general, the viral burden after ATI compared to pre-ART was slightly lower for the control group. However, for transplanted animals the viral load changes were heterogeneous, having much higher ratios for the wild-type (WT) group and slightly higher for CCR5-edited (ΔCCR5) group. For the three computed ratios, the viral load change after ATI was between 10- and 100-fold for the wild-type group (<xref ref-type="fig" rid="fig4">Figure 4B–D</xref>).</p><p>During ATI, CD4<sup>+</sup>CCR5<sup>+</sup> T cells declined heterogeneously in the transplanted groups (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), but CD4<sup>+</sup>CCR5<sup>+</sup> T cell nadirs in the transplanted groups were consistently lower than those of control animals whose CD4<sup>+</sup>CCR5<sup>+</sup> T cell levels did not decrease (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). On the other hand, blood CD4<sup>+</sup>CCR5<sup>-</sup> T cell levels decreased to a similar nadir in all groups during ATI (<xref ref-type="fig" rid="fig4">Figure 4A</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>).</p><p>To summarize, SHIV viral load and CD4<sup>+</sup>CCR5<sup>+</sup> dynamics are heterogeneous among transplanted animals. Higher ATI versus pre-ART viral load ratios in transplanted animals suggest that transplantation affects the host response against SHIV-replication, but this damage to host response may be mitigated somewhat when transplantation includes CCR5-edition.</p></sec><sec id="s2-5"><title>A reduction in SHIV-specific immunity leads to higher viral rebound set points following ATI in transplanted animals</title><p>We simultaneously analyzed the viral and T cell subset data using mechanistic mathematical models in order to recapitulate the heterogeneity of plasma viral load and CD4<sup>+</sup>CCR5<sup>+</sup> T cell kinetics and how transplantation may modify the immune response during ATI compared to the pre-ART stage. We extended our T cell reconstitution model to include SHIV infection of CD4<sup>+</sup>CCR5<sup>+</sup> T cells (<xref ref-type="fig" rid="fig5">Figure 5A</xref> and Methods) and used this second-stage model to analyze virus and T cell dynamics during primary SHIV-infection, ART, transplant, and ATI.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Mathematical model of virus and T cell dynamics following ATI.</title><p>(<bold>A</bold>) Model: Susceptible cells, S, are infected by the virus, V, at rate β. I<sub>p</sub> represents the fraction τ of the infected cells that produce virus, and, I<sub>u</sub>, the other fraction that becomes unproductively infected. Total CD4<sup>+</sup>CCR5<sup>+</sup> T cell count is given by the sum of S, I<sub>p</sub> and I<sub>u</sub>. All infected cells die at rate δ<sub>I</sub>. I<sub>P</sub> cells arise from activation of latently infected cells at rate <inline-formula><mml:math id="inf16"><mml:mrow><mml:mi>ξ</mml:mi><mml:mover accent="true"><mml:mi>L</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> and produce virus at a rate π. Virus is cleared at rate γ. CD8<sup>+</sup> M cells proliferate in the presence of infection with rate ω<sub>8</sub> from which a fraction f become SHIV-specific CD8<sup>+</sup> effector T cells, E<sub>h</sub>, that are removed at a rate d<sub>h</sub>. These effector cells reduce virus production (π) by 1/ (1+θE<sub>h</sub>). Non-susceptible CD4<sup>+</sup> T cells that were not CCR5-edited upregulate CCR5 in the presence of infection and replenish the susceptible pool at rate ω<sub>4</sub>. Gray panels represent mature blood CD4<sup>+</sup> and CD8<sup>+</sup> T cells, and the green panel represents ΔCCR5 cells. (<bold>B</bold>) Individual fits of the model (black lines) to SHIV RNA (left column), blood CD4<sup>+</sup>CCR5<sup>+</sup> T cells (middle column), and CD4<sup>+</sup>CCR5<sup>-</sup> T cells (right column) for one animal in the control (top row), wild type (middle row), and ΔCCR5 groups (bottom row). Shaded areas represent time during ART and dashed-point line, the time of transplantation. (<bold>C–D</bold>) Scatterplots of observed ATI/pre-ART ratio of the (<bold>C</bold>) nadir viral load, and the median viral load ratio versus the SHIV-specific CD8<sup>+</sup> T immunity ATI/pre-ART ratio:<inline-formula><mml:math id="inf17"><mml:mrow><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>ω</mml:mi><mml:mn>8</mml:mn><mml:mrow><mml:mi>A</mml:mi><mml:mi>T</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:msubsup><mml:mo>/</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mi>h</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>T</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>ω</mml:mi><mml:mn>8</mml:mn><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>A</mml:mi><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>/</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mi>h</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>A</mml:mi><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula> (p-values calculated by Pearson’s correlation test); a higher ratio means a better immune response post-ATI. (<bold>D</bold>) Individual estimates of the SHIV-specific CD8<sup>+</sup> T immunity ATI/preART ratio. Blue: control, red: wild type, and green: ΔCCR5 transplant group.</p><p><supplementary-material id="fig5scode1"><label>Figure 5—source code 1.</label><caption><title>Best model file for T cell and virus dynamics from acute infection after ATI in Monolix format.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-57646-fig5-code1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5scode2"><label>Figure 5—source code 2.</label><caption><title>R code for plots in <xref ref-type="fig" rid="fig5">Figure 5B</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-57646-fig5-code2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5scode3"><label>Figure 5—source code 3.</label><caption><title>R code for plots and tests in <xref ref-type="fig" rid="fig5">Figure 5C–D</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-57646-fig5-code3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Competing models for fitting T cell and viral dynamics (<xref ref-type="disp-formula" rid="equ2 equ3">Equations 2-3</xref> in main text) using the best model in <xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref> and fixing parameter values as in <xref ref-type="supplementary-material" rid="fig3sdata3">Figure 3—source data 3</xref>, with AIC values.</title><p>Best fit in bold-red (lowest AIC).</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-57646-fig5-data1-v1.docx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Population parameter estimates for the fits of the model with lowest AIC in <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref> to the T cell and virus dynamics.</title><p>RSE: relative standard error. Empty fields represent cases when the standard deviation of random effects, <inline-formula><mml:math id="inf18"><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mi>ψ</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, was fixed to zero. Values of <inline-formula><mml:math id="inf19"><mml:mover accent="true"><mml:mi>ψ</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:math></inline-formula> for <inline-formula><mml:math id="inf20"><mml:mrow><mml:mi>β</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>ω</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>ω</mml:mi><mml:mn>8</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>, and <inline-formula><mml:math id="inf21"><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> shown here are transformed assuming a blood volume of 3 × 10<sup>5</sup> μL (calculated assuming blood:weight ratio of 60 mL/kg and body weight of 5 kg). Red values represent an RSE greater than 100% implying that the number of data points may not be enough to estimate the respective parameter.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-57646-fig5-data2-v1.docx"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Individual parameter estimates for the fits of the model in <xref ref-type="disp-formula" rid="equ2 equ3">Equations 2-3</xref> in main text (lowest AIC in <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>) to the T cell and virus dynamics.</title><p>Values of <inline-formula><mml:math id="inf22"><mml:mover accent="true"><mml:mi>ψ</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:math></inline-formula> for <inline-formula><mml:math id="inf23"><mml:mrow><mml:mi>β</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>ω</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>ω</mml:mi><mml:mn>8</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>, and <inline-formula><mml:math id="inf24"><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> shown here are transformed assuming a blood volume of 3 × 10<sup>5</sup> μL (calculated assuming blood:weight ratio of 60 mL/kg and body weight of 5 kg). Shown are individual estimates for animals that continued study after ATI.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-57646-fig5-data3-v1.docx"/></supplementary-material></p><p><supplementary-material id="fig5sdata4"><label>Figure 5—source data 4.</label><caption><title>Individual parameter estimates obtained from Monolix for the best fits used in the R code for <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-57646-fig5-data4-v1.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57646-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Individual fits of the best model to the blood T cell and viral load observations before/after ATI for control group.</title><p>Empirical data for peripheral T cell subset counts and plasma viral load (blue data points) and best fits of the model in <xref ref-type="disp-formula" rid="equ2 equ3">Equations 2 and 3</xref> to all blood T cell subsets before/after ATI for the control group. Dashed-dot lines: ART initiation and time relative to transplantation with respect to the other groups; dotted line: ATI. Each row is one animal (ID in the leftmost graph per row).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57646-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Individual fits of the best model to the blood T cell and viral load observations before/after ATI for the wild-type-transplant group.</title><p>Empirical data for peripheral T cell subset counts and plasma viral load (red data points) and best fits of the model in <xref ref-type="disp-formula" rid="equ2 equ3">Equations 2 and 3</xref> to all viral load observations and blood T cell subsets before/after ATI for the wild-type-transplant group (solid lines). Dashed-dot lines: ART initiation and transplantation; dotted line: ATI. Each row is one animal (ID in the leftmost graph per row).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57646-fig5-figsupp2-v1.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Individual fits of the best model to the blood T cell and viral load observations before/after ATI for the ΔCCR5-transplant group.</title><p>Empirical data for peripheral T cell subset counts and plasma viral load (green data points) and best fits of the model in <xref ref-type="disp-formula" rid="equ2 equ3">Equations 2 and 3</xref> to all viral load observations and blood T cell subsets before/after ATI for the ΔCCR5-transplant group (solid lines). Dashed-dot lines: ART initiation and transplantation; dotted line: ATI. Each row is one animal (ID in the leftmost graph per row).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57646-fig5-figsupp3-v1.tif"/></fig></fig-group><p>Again, following model selection theory based on AIC, we compared six mechanistic models and found a parsimonious model to explain the data (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>). This model simultaneously recapitulates plasma viral load and the kinetics of CD4<sup>+</sup> CCR5<sup>+</sup> and CCR5<sup>-</sup> T cells as shown in <xref ref-type="fig" rid="fig5">Figure 5B</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplements 1</xref>–<xref ref-type="fig" rid="fig5s3">3</xref> with corresponding estimated parameters in <xref ref-type="supplementary-material" rid="fig5sdata2">Figure 5—source datas 2</xref> and <xref ref-type="supplementary-material" rid="fig5sdata3">3</xref>. In the best fitting model, parameters related to immune response against infection: the SHIV-specific CD8<sup>+</sup> T cell proliferation (<inline-formula><mml:math id="inf25"><mml:mrow><mml:msub><mml:mi>ω</mml:mi><mml:mn>8</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>), saturation (<inline-formula><mml:math id="inf26"><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>), and death rates (<inline-formula><mml:math id="inf27"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>h</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>) were different during ATI and the pre-ART stage (see <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>; <xref ref-type="bibr" rid="bib64">Reeves et al., 2017</xref>). SHIV-specific CD8<sup>+</sup> effector cells reduce virus production rather than killing infected cells (<xref ref-type="bibr" rid="bib22">Elemans et al., 2011</xref>; <xref ref-type="bibr" rid="bib40">Klatt et al., 2010</xref>; <xref ref-type="bibr" rid="bib83">Wong et al., 2010</xref>), possibly by secretion of HIV-antiviral factors (<xref ref-type="bibr" rid="bib70">Shridhar et al., 2014</xref>; <xref ref-type="bibr" rid="bib4">Blazek et al., 2016</xref>; <xref ref-type="bibr" rid="bib85">Zhang et al., 2002</xref>)—not explicitly included in the model. The model also suggests that infection enhances upregulation of CD4<sup>+</sup>CCR5<sup>-</sup> T cells. This upregulation transiently reduces the CD4<sup>+</sup>CCR5<sup>-</sup> compartment and replenishes CD4<sup>+</sup>CCR5<sup>+</sup> T cells after ATI (<xref ref-type="bibr" rid="bib21">Douek et al., 2003</xref>; <xref ref-type="bibr" rid="bib50">Okoye et al., 2007</xref>; <xref ref-type="bibr" rid="bib51">Okoye et al., 2012</xref>). Finally, in this model, some of the ΔCCR5-gene-modified CD4<sup>+</sup> T cells also have kinetics similar to non-modified CD4<sup>+</sup>CCR5<sup>+</sup> cells (i.e. it includes the compartment <italic>N<sub>p</sub></italic><sub>2</sub> as in <xref ref-type="fig" rid="fig5">Figure 5A</xref>), whereas this was not able to be differentiated in the first-stage modeling.</p><p>We used our model to compute the SHIV-specific CD8<sup>+</sup> T cell turnover rates after ATI and during pre-ART as measures of SHIV-specific immunity (<inline-formula><mml:math id="inf28"><mml:mrow><mml:mi>S</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:math></inline-formula>) for each stage, that is, <inline-formula><mml:math id="inf29"><mml:mrow><mml:mi>S</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>T</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>ω</mml:mi><mml:mn>8</mml:mn><mml:mrow><mml:mi>A</mml:mi><mml:mi>T</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>d</mml:mi><mml:mi>h</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>T</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf30"><mml:mrow><mml:mi>S</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>A</mml:mi><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>ω</mml:mi><mml:mn>8</mml:mn><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>A</mml:mi><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>d</mml:mi><mml:mi>h</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>A</mml:mi><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula>, respectively. We found that the SHIV immunity ATI/pre-ART ratio <inline-formula><mml:math id="inf31"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mi>S</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>T</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>A</mml:mi><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> correlated negatively with the ATI/pre-ART ratio of the observed nadir and median viral loads (<xref ref-type="fig" rid="fig5">Figure 5C–D</xref>). In this sense, the viral burden increase during ATI (viral burden ratio &gt;1) in animals in the transplant groups might be due to the underlying loss of the immune response to the virus (<inline-formula><mml:math id="inf32"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>S</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>T</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>A</mml:mi><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, <xref ref-type="fig" rid="fig5">Figure 5C–D</xref>). Similarly, decrease in viral burden during ATI (viral burden ratio &lt;1) in animals in control and ΔCCR5 groups might be due immune response memory or its recovery, respectively (<inline-formula><mml:math id="inf33"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>S</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>T</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>A</mml:mi><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&gt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, <xref ref-type="fig" rid="fig5">Figure 5C–D</xref>).</p><p>In conclusion, we developed a second-stage model that simultaneously recapitulates viral and T cell dynamics from SHIV-infected animals receiving autologous HSPC transplantation. The model suggests that transplant may reduce host T-cell immunity resulting in higher viral loads after ATI compared to the pre-ART stage. However, SHIV immunity might be recovered if CCR5 disruption is added in the transplant resulting in lower viral loads after ATI.</p></sec><sec id="s2-6"><title>Post-ATI viral control requires a large HSPC dose containing a high fraction of CCR5-edited cells</title><p>An important advantage of our model is the ability to calculate the conditions required for post-ATI viral control (viral load set point &lt;30 copies/ml) after CCR5-edited autologous transplant. To this end, we used our second-stage model to approximate an effective reproductive ratio <inline-formula><mml:math id="inf34"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> to describe the ability of the virus to sustain infection after ATI in transplanted animals (see Materials and methods):<disp-formula id="equ1"><label>(1)</label><mml:math id="m1"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>Here, <inline-formula><mml:math id="inf35"><mml:mrow><mml:mo> </mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> describes the fraction of protected HSPCs in the transplant product, <inline-formula><mml:math id="inf36"><mml:mi>D</mml:mi></mml:math></inline-formula> the dose or total number of infused HSPCs, and <inline-formula><mml:math id="inf37"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> the number of residual endogenous HSPCs after conditioning (variable <inline-formula><mml:math id="inf38"><mml:mrow><mml:mo> </mml:mo><mml:mi>P</mml:mi></mml:mrow></mml:math></inline-formula> at time of transplant, <xref ref-type="fig" rid="fig3">Figure 3A</xref>). <inline-formula><mml:math id="inf39"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> is the approximate number of new infections caused by one infected cell after T cell complete reconstitution post-conditioning as defined in <xref ref-type="disp-formula" rid="equ4">Equation 4</xref> (see Materials and methods) and is inversely related to the anti-SHIV immune response at the time of ATI. Post-ATI viral control depends on the fraction of protected HSPCs in the body immediately after transplant that are protected from SHIV infection, or <inline-formula><mml:math id="inf40"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>.</p><p>To estimate the values of <inline-formula><mml:math id="inf41"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="inf42"><mml:mi>D</mml:mi></mml:math></inline-formula>, and <inline-formula><mml:math id="inf43"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> needed for viral control, we first estimated <inline-formula><mml:math id="inf44"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> for each animal based on individual parameter estimates pertaining to SHIV virulence and anti-SHIV immunity. We then simulated the model for each animal using varying values of <italic>f<sub>p</sub></italic> from zero to one (0–100% CCR5-edited HSPCs), values of <inline-formula><mml:math id="inf45"><mml:mi>D</mml:mi></mml:math></inline-formula> from 10<sup>6</sup> to 10<sup>9</sup> HSPCs, and values of <inline-formula><mml:math id="inf46"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> from zero to 10<sup>7</sup> HSPCs. As an illustration, <xref ref-type="fig" rid="fig6">Figure 6A</xref> depicts projections of the model for ΔCCR5-transplanted animal A11219 for a range of values of <inline-formula><mml:math id="inf47"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> when <inline-formula><mml:math id="inf48"><mml:mrow><mml:mi>D</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mn>7</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> HSPCs/kg and <inline-formula><mml:math id="inf49"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>6</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mn>6</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> HSPCs. When <inline-formula><mml:math id="inf50"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="inf51"><mml:mi>D</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="inf52"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> resulted in <inline-formula><mml:math id="inf53"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, plasma virus was not controlled following viral rebound post-ATI. When <inline-formula><mml:math id="inf54"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> &lt; 1, post-rebound control was observed, but only at weeks 40–60 post-ATI, following an initial decrease in viral loads beginning 30–40 weeks after ATI. In this case, post-rebound control occurred concomitantly with ΔCCR5 CD4<sup>+</sup> T cell complete reconstitution relative to non-edited CCR5<sup>+/-</sup> CD4<sup>+</sup> T cells (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Lower values of <inline-formula><mml:math id="inf55"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> resulted in earlier post-rebound control (earliest ~40 weeks).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Model predictions of factors governing post-rebound viral control after CCR5 gene-edited hematopoietic stem and progenitor cell (HSPC) transplant.</title><p>(<bold>A</bold>) Predictions for plasma viral loads post-ATI using the optimized mathematical model. Here, <inline-formula><mml:math id="inf56"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and is the composite determinant of viral control. Parameter estimates for animal A11219 (<xref ref-type="supplementary-material" rid="fig5sdata3">Figure 5—source data 3</xref>) were used to compute the effective reproductive ratio <inline-formula><mml:math id="inf57"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mo> </mml:mo></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>. Higher values of <inline-formula><mml:math id="inf58"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mo> </mml:mo></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> imply poorer anti-SHIV immunity and high virulence (see <xref ref-type="disp-formula" rid="equ4">Equation 4</xref> in Materials and methods). We varied values of the fraction of HSPCs in transplant <inline-formula><mml:math id="inf59"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, the stem cell dose <inline-formula><mml:math id="inf60"><mml:mi>D</mml:mi></mml:math></inline-formula> as shown, and fixed the remaining number of HSPCs after TBI before transplant <inline-formula><mml:math id="inf61"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>6</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mn>6</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula>. <inline-formula><mml:math id="inf62"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> predicted spontaneous viral control 40–60 weeks after ATI. (<bold>B</bold>) A simulation with <inline-formula><mml:math id="inf63"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.7</mml:mn></mml:mrow></mml:math></inline-formula> demonstrates CCR5-edited CD4+ T cell recovery is concurrent with viral control. (<bold>C</bold>) Model predictions of the fraction of protected HSPCs in the transplant <inline-formula><mml:math id="inf64"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> (y-axis) and the ratio of transplanted HSPCs to total infused plus remaining post-TBI HSPCs <inline-formula><mml:math id="inf65"><mml:mrow><mml:mi>D</mml:mi><mml:mo>:</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> (x-axis) required for spontaneous viral control. The heatmap shown corresponds to animal A11200 which has <inline-formula><mml:math id="inf66"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>4</mml:mn><mml:mo> </mml:mo></mml:mrow></mml:math></inline-formula>, the lowest predicted <inline-formula><mml:math id="inf67"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> (76%) and <inline-formula><mml:math id="inf68"><mml:mrow><mml:mi>D</mml:mi><mml:mo>:</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> (~5) required for post-ATI viral control (heatmaps for other animals in <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>). Blue shaded region represents the parameter space with post-ATI viral control or <inline-formula><mml:math id="inf69"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>. Yellow-to-red region represent the parameter space with no control or <inline-formula><mml:math id="inf70"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>. Data points represent the individual values of <inline-formula><mml:math id="inf71"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf72"><mml:mrow><mml:mi>D</mml:mi><mml:mo>:</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo> </mml:mo></mml:mrow></mml:math></inline-formula> from each transplanted animal in the study. (<bold>D</bold>) Model predictions of the minimum fraction of protected HSPCs in the body <inline-formula><mml:math id="inf73"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> for viral control (y-axis) for each animal given their calculated values for <inline-formula><mml:math id="inf74"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> (x-axis). In all cases, the minimum <inline-formula><mml:math id="inf75"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> corresponded to <inline-formula><mml:math id="inf76"><mml:mrow><mml:mfrac><mml:mi>D</mml:mi><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mo>&gt;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:math></inline-formula> (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>). Each color is an animal, and A11200 is the red diamond with the lowest value of min <inline-formula><mml:math id="inf77"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>. p-Value calculated using Pearson’s correlation test.</p><p><supplementary-material id="fig6scode1"><label>Figure 6—source code 1.</label><caption><title>R code for plots in <xref ref-type="fig" rid="fig6">Figure 6A–B</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-57646-fig6-code1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6scode2"><label>Figure 6—source code 2.</label><caption><title>R code for plots in <xref ref-type="fig" rid="fig6">Figure 6C–D</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-57646-fig6-code2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Results from all simulations varying <italic>f<sub>p</sub></italic>, <italic>D</italic>, and <italic>P<sub>r</sub></italic>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-57646-fig6-data1-v1.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57646-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Model predictions for post-rebound viral control after CCR5 gene-edited hematopoietic stem and progenitor cell (HSPC) transplantation based on <inline-formula><mml:math id="inf78"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>.</title><p>Model predictions of the effective reproductive ratio <inline-formula><mml:math id="inf79"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo> </mml:mo></mml:mrow></mml:math></inline-formula> that lead to post-ATI viral control or not. <inline-formula><mml:math id="inf80"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> was computed using varying values of <inline-formula><mml:math id="inf81"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>: fraction of HSPCs in transplant, <inline-formula><mml:math id="inf82"><mml:mi>D</mml:mi></mml:math></inline-formula>: total amount of infused HSPCs and <inline-formula><mml:math id="inf83"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>: remaining number of HSPCs after TBI before transplant and using parameter estimates from all animals (<xref ref-type="supplementary-material" rid="fig5sdata3">Figure 5—source data 3</xref>) to estimate <inline-formula><mml:math id="inf84"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> from <xref ref-type="disp-formula" rid="equ4">Equation 4</xref> in the main text.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57646-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Model predictions of the fraction of protected hematopoietic stem and progenitor cell (HSPCs) in the transplant <inline-formula><mml:math id="inf85"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> (y-axis) and the fraction of transplanted HSPCs with respect to the total infused plus remaining post-TBI HSPCs <inline-formula><mml:math id="inf86"><mml:mrow><mml:mi>D</mml:mi><mml:mo>:</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> (x-axis) required for spontaneous viral control.</title><p>Blue color represents the parameter space with post-ATI viral control or <inline-formula><mml:math id="inf87"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>. Yellow-to-red colors represent the parameter space with no control or <inline-formula><mml:math id="inf88"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>. Data points (green and red shapes) represent the individual values of <inline-formula><mml:math id="inf89"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf90"><mml:mrow><mml:mi>D</mml:mi><mml:mo>:</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mtext> </mml:mtext></mml:mrow></mml:math></inline-formula> from each transplanted animal in the study, assuming <inline-formula><mml:math id="inf91"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mn>7</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> HSPCs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57646-fig6-figsupp2-v1.tif"/></fig></fig-group><p>Indeed, for all animals, post-treatment control occurred when values of <inline-formula><mml:math id="inf92"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="inf93"><mml:mi>D</mml:mi></mml:math></inline-formula>, and <inline-formula><mml:math id="inf94"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> resulted in <inline-formula><mml:math id="inf95"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Model predictions for animal A11200 demonstrate that regardless of the fraction of protected HSPCs in the transplant (<inline-formula><mml:math id="inf96"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>), viral control is possible only when the ratio of HSPCs in the transplant to the residual endogenous HSPCs in the body post-TBI (<inline-formula><mml:math id="inf97"><mml:mrow><mml:mi>D</mml:mi><mml:mo>:</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>) is above 5 (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Moreover, if the ratio <inline-formula><mml:math id="inf98"><mml:mrow><mml:mi>D</mml:mi><mml:mo>:</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> is greater than 5, the minimum fraction of protected cells required is 76%, and further increasing <inline-formula><mml:math id="inf99"><mml:mrow><mml:mi>D</mml:mi><mml:mo>:</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> does not decrease <inline-formula><mml:math id="inf100"><mml:mrow><mml:mo> </mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> significantly. From all transplanted animals we found that the minimum fraction of protected cells in the transplant <inline-formula><mml:math id="inf101"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> varied from 76% to 94% and was positively correlated with a weaker anti-SHIV immune response of the given animal defined by <inline-formula><mml:math id="inf102"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> (<xref ref-type="fig" rid="fig6">Figure 6D</xref> and <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>). This is consistent with <xref ref-type="disp-formula" rid="equ1">Equation 1</xref> as <inline-formula><mml:math id="inf103"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>≈</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> when <inline-formula><mml:math id="inf104"><mml:mrow><mml:mi>D</mml:mi><mml:mo>≫</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>. <inline-formula><mml:math id="inf105"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> varied from 4 to 16 across animals using individual parameter estimates in <xref ref-type="supplementary-material" rid="fig5sdata3">Figure 5—source data 3</xref>. The required levels for <inline-formula><mml:math id="inf106"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> are lower in the context of more intense anti-SHIV immunologic pressure and lower viral strength. This result argues for strategies that (1) augment anti-SHIV immunity despite conditioning (lower <inline-formula><mml:math id="inf107"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> using SHIV-specific CAR T cells, therapeutic vaccination, etc.), (2) increase the stem cell dose relative to the residual endogenous stem cells (<inline-formula><mml:math id="inf108"><mml:mrow><mml:mi>D</mml:mi><mml:mo>:</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>) after transplant—perhaps by enhancing potency of the conditioning regimen, and (3) increase the fraction of gene-modified, SHIV-resistant cells <inline-formula><mml:math id="inf109"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>.</p><p>Based on the observation that viral control occurred when CD4<sup>+</sup> T cell subsets approached a steady state in the simulations (<xref ref-type="fig" rid="fig6">Figure 6A–B</xref>), we simulated the model again to determine whether viral control might occur faster if ATI was postponed at a time when more mature, protected cells have expanded. As an illustration, we simulated animal A11219 under conditions that lead to viral control: <inline-formula><mml:math id="inf110"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>0.95</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="inf111"><mml:mrow><mml:mi>D</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mn>8</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> HSPCs and <inline-formula><mml:math id="inf112"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mn>7</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> HSPCs with ATI occurring at 3, 14, 25, or 37 weeks after transplantation. Indeed, time to post-ATI viral control (shaded areas in <xref ref-type="fig" rid="fig7">Figure 7A</xref>) decreased as time to ATI was extended after transplant and as the difference between CD4<sup>+</sup>CCR5<sup>-</sup> cell density at ATI and its expected set point decreased (shaded areas in <xref ref-type="fig" rid="fig7">Figure 7B</xref>). In this case, ΔCCR5 CD4<sup>+</sup> T cells comprised the majority of the CD4<sup>+</sup>CCR5<sup>-</sup> T cell compartment (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). Further, we simulated increasing times of ATI using parameter estimates for all transplanted animals but under conditions that lead to viral control (<inline-formula><mml:math id="inf113"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>0.95</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="inf114"><mml:mrow><mml:mi>D</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mn>8</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> HSPCs and <inline-formula><mml:math id="inf115"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mn>7</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> HSPCs). The model predicted the same decreasing pattern with times between transplant and ATI required to avoid viral rebound from 20 to 60 weeks (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). This timeframe allowed all animals to achieve viral control due to CD4<sup>+</sup>CCR5<sup>-</sup> cell densities at ATI exceeding 60–90% of the ultimate steady state value (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). As in <xref ref-type="fig" rid="fig7">Figure 7B</xref> for all animals ΔCCR5 CD4<sup>+</sup> T cells comprised the majority of the CD4<sup>+</sup>CCR5<sup>-</sup> T cell compartment.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Model predictions of time to post-ATI viral control given varying times for the start of ATI.</title><p>(<bold>A-B</bold>) Examples of projected (<bold>A</bold>) viral load and (<bold>B</bold>) total, modified and unmodified CD4<sup>+</sup> CCR5<sup>-</sup> (solid) and ΔCCR5 CD4<sup>+</sup> T cells (dashed) from the model for animal A11219 when <inline-formula><mml:math id="inf116"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>0.95</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="inf117"><mml:mrow><mml:mi>D</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>8.5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> HSPCs and <inline-formula><mml:math id="inf118"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mn>7</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> HSPCs, for different times of ATI (<inline-formula><mml:math id="inf119"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>T</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>=3, 14, 25, and 37 weeks after transplantation). Dashed-dotted vertical lines represent time of transplant. Shaded areas between the dotted lines in (<bold>A</bold>) describe the time from ATI until spontaneous viral control. Shaded areas between the blue dashed lines in (<bold>B</bold>) represent the difference between the CD4<sup>+</sup> CCR5<sup>-</sup> T cell concentration at ATI and the projected steady state. Dotted lines in (<bold>B</bold>) represent time of ATI. (<bold>C–D</bold>) Model predictions of the (<bold>C</bold>) time until viral control after ATI and (<bold>D</bold>) the fraction of total CD4<sup>+</sup> CCR5<sup>-</sup> T cell concentration at ATI with respect to its steady state conditions given actual estimated parameter values for each transplanted macaque when <inline-formula><mml:math id="inf120"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>0.95</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="inf121"><mml:mrow><mml:mi>D</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>8.5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> HSPCs and <inline-formula><mml:math id="inf122"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mn>7</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> HSPCs.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Results from all simulations varying time to ATI.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-57646-fig7-data1-v1.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57646-fig7-v1.tif"/></fig><p>In summary, our model predicts that post-ATI viral control during autologous HSPC transplantation is obtained when (1) the transplanted HSPC dose is significantly higher than the residual endogenous HSPCs that persist through myeloablative conditioning (in this case TBI) <italic>and</italic> (2) the fraction of protected (i.e. CCR5-edited) HSPCs in the transplant <inline-formula><mml:math id="inf123"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is sufficiently high to outcompete cells susceptible to infection and disrupt ongoing cycles of viral replication. Spontaneous post-rebound control occurs after CCR5<sup>-</sup> CD4<sup>+</sup> T cells achieve a steady state approximately 1-year after transplantation. Hence, our model suggests that, under the two described conditions, prolonging time to ATI (at least 1-year post-transplantation) may increase the likelihood of rapid viral control post-ATI. Moreover, specifically tracking CD4<sup>+</sup>CCR5<sup>-</sup> (or CCR5-edited CD4<sup>+</sup>) T cell growth and waiting for steady-state could be used as a surrogate for the decision to undergo ATI.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Here we introduce a data-validated mathematical model that, to our knowledge, is the first to simultaneously recapitulate viral loads as well as CD4<sup>+</sup> and CD8<sup>+</sup> T cell subset counts in a macaque model of suppressed HIV-1 infection. In addition, our model is the first to describe dynamics of CCR5<sup>+</sup> and CCR5<sup>-</sup> T cells within the CD4 compartment. We performed extensive, systematic data fitting comparing 30 mechanistic models to arrive at a set of equations that most parsimoniously explains the available data. In multiple stages of modeling, we recapitulated (1) peripheral CD4<sup>+</sup> and CD8<sup>+</sup> T cell subset reconstitution dynamics following transplant and (2) T cell subset dynamics and SHIV viral rebound following ATI. Before ATI, all animals had suppressed plasma viral loads below the limit of detection, allowing analysis of T cell reconstitution dynamics independent of virus-mediated pressure. At each step, we applied model selection theory to select the simplest set of mechanisms capable of explaining the observed data (<xref ref-type="bibr" rid="bib8">Burnham et al., 2002</xref>). Our model predicts that post-rebound viral control might be possible during autologous gene-edited HSPC transplantation if therapy achieves (1) a sufficient fraction of gene-protected, autologous HSPCs (2) a high dose of transplant product relative to a residual endogenous population of stem cells that persists following conditioning, and (3) enhancement of SHIV-specific immune responses following transplantation. Further, our model predicts, that under these conditions, spontaneous viral control after ATI is likely if ΔCCR5 T cells (tracked by CD4<sup>+</sup>CCR5<sup>-</sup> T cells) are allowed to reconstitute prior to ATI. These results are consistent with the cure achieved by the Berlin and London Patients who received a transplant with 100% HIV-resistant cells after intense conditioning (<xref ref-type="bibr" rid="bib1">Allers et al., 2011</xref>; <xref ref-type="bibr" rid="bib36">Hütter et al., 2009</xref>). In the autologous setting where 100% CCR5 editing may not be feasible, adjunctive measures that augment virus-specific immunity, such as therapeutic vaccination, infusion of HIV-specific chimeric antigen receptor (CAR) T cells or use of neutralizing antibodies, may synergize with HSPC transplantation to achieve post-treatment control (<xref ref-type="bibr" rid="bib29">Haworth et al., 2017</xref>; <xref ref-type="bibr" rid="bib86">Zhen et al., 2017</xref>).</p><p>Although the model predicts a potential benefit for more potent conditioning that favors engraftment of SHIV-resistant cells, a more aggressive conditioning regimen may also deplete SHIV-specific immune responses and lead to less favorable toxicity profiles. On the other hand, in the absence of conditioning, the number of endogenous HSPCs will remain too high. Thus, post-rebound control following ΔCCR5 transplant requires not only highly potent myeloablative conditioning, it also requires a higher percentage of gene-edited cells to counteract the loss of SHIV-specific immunity. Furthermore, due to the high levels of endogenous HSPCs and lack of an engraftment ‘niche’, the long-term persistence of transplanted, CCR5-edited HSPC would be exceedingly low. Alternatively, non-genotoxic conditioning regimens that target only HSPC for transplantation may prevent the loss of SHIV-specific immune cells (<xref ref-type="bibr" rid="bib53">Palchaudhuri et al., 2016</xref>; <xref ref-type="bibr" rid="bib15">Czechowicz et al., 2019</xref>; <xref ref-type="bibr" rid="bib73">Srikanthan et al., 2020</xref>).</p><p>We previously demonstrated the link between disruption of the immune response during transplant and increased magnitude of viral rebound during treatment interruption (<xref ref-type="bibr" rid="bib58">Peterson et al., 2017</xref>; <xref ref-type="bibr" rid="bib64">Reeves et al., 2017</xref>). Here, we confirm that the increase of viral load median and nadir at ATI compare to the pre-ART stage is correlated with the reduction of the SHIV-specific immune response during transplant, but also predict that a reduction of viral load burden at ATI compared to pre-ART in animals receiving CCR5-edited cells in the transplant is correlated to a recovery of the SHIV-specific immunity.</p><p>Our results are somewhat limited by a small sample size of 22 animals, only 12 of which underwent ΔCCR5 transplant. For that reason, several model parameters were assumed to be the same among all animals (i.e. without random effects). However, the number of observations for each animal was large enough to discriminate among several different plausible model candidates. Due to the small sample size, we also performed projections by varying the parameters related to transplantation (i.e. dose, fraction of protected cells, and residual endogenous HSPCs) and using only the estimated individual parameters rather than sampling from estimated population distributions. Reassuringly, our results align with prior mechanistic studies of cellular reconstitution after stem cell transplantation (<xref ref-type="bibr" rid="bib37">Jameson, 2002</xref>; <xref ref-type="bibr" rid="bib20">Douek et al., 2000</xref>; <xref ref-type="bibr" rid="bib26">Guillaume et al., 1998</xref>; <xref ref-type="bibr" rid="bib41">Krenger et al., 2011</xref>; <xref ref-type="bibr" rid="bib65">Roux et al., 2000</xref>). Our analysis also suggests that the majority of reconstituting CD4<sup>+</sup>CCR5<sup>-</sup> T cells do not proliferate and have slow rates consistent with estimates of thymic export from previous studies (<xref ref-type="bibr" rid="bib20">Douek et al., 2000</xref>; <xref ref-type="bibr" rid="bib41">Krenger et al., 2011</xref>; <xref ref-type="bibr" rid="bib65">Roux et al., 2000</xref>).</p><p>Recent studies from our group and others make clear that although a preparative conditioning regimen (e.g. TBI) is essential to maximize engraftment of transplanted HSPCs, it does not clear 100% of host lymphocytes, especially those in tissues (<xref ref-type="bibr" rid="bib58">Peterson et al., 2017</xref>; <xref ref-type="bibr" rid="bib59">Peterson et al., 2018</xref>; <xref ref-type="bibr" rid="bib18">Donahue et al., 2015</xref>; <xref ref-type="bibr" rid="bib62">Radtke et al., 2017</xref>). The best fitting model predicts that incomplete elimination of lymphocytes by TBI prevents CD4<sup>+</sup>CCR5<sup>-</sup> cells from predominating post-transplant. We found that the rapid expansion of CD4<sup>+</sup>CCR5<sup>+</sup> and CD8<sup>+</sup> T cells during the first few weeks after HSPC transplantation is most likely due to lymphopenia-induced proliferation of residual endogenous cells after TBI rather than thymic reconstitution. CD4<sup>+</sup>CCR5<sup>-</sup> T cells arising from thymic export of both transplanted and remaining cells are overwhelmed by more rapidly populating CD4<sup>+</sup>CCR5<sup>+</sup> T cells within weeks of transplantation. Going forward, we will need to identify anatomic sites (namely viral reservoir tissues such as spleen and lymph nodes) and associated mechanisms that allow activated CD4<sup>+</sup>CCR5<sup>+</sup> to survive conditioning.</p><p>A final important observation from our model is that CD4<sup>+</sup> T cell kinetics conducive to viral control may not be reached until 20–60 weeks after transplant. Therefore, our model suggests that ATI should be delayed until CD4<sup>+</sup>CCR5<sup>-</sup> T cells reconstitute (as a proxy for ΔCCR5 CD4<sup>+</sup> T cell reconstitution) to their natural steady state. Furthermore, optimized timing of ATI would ideally be based on reconstitution of all CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets ensuring approximately steady state levels before discontinuing ART.</p><p>In conclusion, our mathematical model recapitulates, to an unprecedented degree of accuracy and detail, the complex interplay between reconstituting SHIV-susceptible CD4<sup>+</sup> T cells, SHIV-resistant CD4<sup>+</sup> T cells, infected cells, virus-specific immune cells, and replicating virus following autologous, CCR5-edited HSPC transplantation. Our results illustrate the capabilities of mathematical models to glean insight from preclinical animal models and highlight that modeling will be required to optimize strategies for HIV cure.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Study design</title><p>We employed a multi-stage approach using ordinary differential equation models of cellular and viral dynamics to analyze data from SHIV-infected pig-tailed macaques that underwent autologous HSPC transplantation during ART and to find conditions for post-rebound control when gene-edited cells were included in the transplant product. First, we modeled T cell dynamics and reconstitution following transplant and before ATI, assuming that low viral loads during suppressive ART do not affect cell dynamics (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). In the second stage, we added viral load data during primary infection and after ATI and fit models to the T cell and viral dynamics simultaneously from data pre- and post-ATI (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). We then used the most parsimonious model, as determined by AIC, to perform simulated experiments for different transplant conditions, focusing on variables including fraction of protected cells, dose, depletion of HSPCs after conditioning, and time of ATI after transplant to find thresholds for viral control post-ATI.</p></sec><sec id="s4-2"><title>Experimental data</title><p>Twenty-two juvenile pigtail macaques were intravenously challenged with 9500 TCID50 SHIV-1157ipd3N4 (SHIV-C) (<xref ref-type="bibr" rid="bib58">Peterson et al., 2017</xref>; <xref ref-type="bibr" rid="bib59">Peterson et al., 2018</xref>). After 6 months, the macaques received combination antiretroviral therapy (ART): tenofovir (PMPA), emtricitabine (FTC), and raltegravir (RAL). After ~30 weeks on ART, 17 animals received total body irradiation (TBI) followed by transplantation of autologous HSPCs. In 12/17 animals the transplant product included CCR5 gene-edited HSPCs (ΔCCR5 group); HSPC products in 5/17 animals were not edited (WT group). After an additional 25 weeks following transplant, when viral load was well suppressed, animals underwent ATI (<xref ref-type="bibr" rid="bib58">Peterson et al., 2017</xref>). A control group of five animals did not receive TBI or HSPC transplantation and underwent ATI after ~50 weeks of treatment. One and six of the animals in the WT and ΔCCR5 groups, respectively, were necropsied before ATI. One of the animals in the control group was necropsied before ATI (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Plasma viral loads and absolute peripheral T-cell counts from CD4<sup>+</sup>CCR5<sup>-</sup>, CD4<sup>+</sup>CCR5<sup>+</sup> and total CD8<sup>+</sup> and subsets (naive, central memory [T<sub>CM</sub>], and effector memory [T<sub>EM</sub>]) were measured for the control and WT group as described previously (<xref ref-type="bibr" rid="bib58">Peterson et al., 2017</xref>). We analyzed peripheral T cell counts and plasma viral load from infection until 43 weeks post-transplant (~25 weeks pre-ATI and ~20 weeks post-ATI).</p></sec><sec id="s4-3"><title>Mathematical modeling of T cell reconstitution dynamics</title><p>We modeled the kinetics of CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets in blood including residual endogenous, transplanted cells that home to the BM, and progenitor cells in the BM/thymus both from transplant and residual endogenous. We included CD8<sup>+</sup> T cells in the model because CD8<sup>+</sup> and CD4<sup>+</sup> T cells may arise from new naïve cells from the thymus and compete with each other for resources that impact clonal expansion and cell survival (<xref ref-type="bibr" rid="bib37">Jameson, 2002</xref>; <xref ref-type="bibr" rid="bib49">Mehr and Perelson, 1997</xref>; <xref ref-type="bibr" rid="bib45">Margolick and Donnenberg, 1997</xref>). We assumed that expansion of CD4<sup>+</sup> and CD8<sup>+</sup> T cells in the blood derives from: (1) export of naïve cells differentiated from a progenitor compartment in the BM/Thymus (<xref ref-type="bibr" rid="bib26">Guillaume et al., 1998</xref>; <xref ref-type="bibr" rid="bib71">Spits, 2002</xref>) ([either from transplanted (<xref ref-type="bibr" rid="bib20">Douek et al., 2000</xref>; <xref ref-type="bibr" rid="bib19">Douek et al., 1998</xref>)] or residual endogenous CD34<sup>+</sup> HSPCs) and further differentiation to an activated effector state (<xref ref-type="bibr" rid="bib80">Voehringer et al., 2008</xref>; <xref ref-type="bibr" rid="bib2">Bender et al., 1999</xref>; <xref ref-type="bibr" rid="bib39">Kieper and Jameson, 1999</xref>; <xref ref-type="bibr" rid="bib67">Sallusto et al., 2004</xref>; <xref ref-type="bibr" rid="bib44">Le Saout et al., 2008</xref>; <xref ref-type="bibr" rid="bib72">Sprent and Surh, 2011</xref>; <xref ref-type="bibr" rid="bib7">Buchholz et al., 2013</xref>; <xref ref-type="bibr" rid="bib23">Farber et al., 2014</xref>; <xref ref-type="bibr" rid="bib38">Kaech et al., 2002</xref>), or (2) lymphopenia-induced division of mature, residual endogenous cells that persist through myeloablative TBI (<xref ref-type="bibr" rid="bib37">Jameson, 2002</xref>; <xref ref-type="bibr" rid="bib69">Schluns et al., 2002</xref>; <xref ref-type="bibr" rid="bib68">Schluns et al., 2000</xref>; <xref ref-type="bibr" rid="bib25">Goldrath et al., 2004</xref>; <xref ref-type="bibr" rid="bib80">Voehringer et al., 2008</xref>) as factors that drive T cell proliferation are more accessible (i.e. self-MHC molecules on antigen-presenting cells [<xref ref-type="bibr" rid="bib2">Bender et al., 1999</xref>; <xref ref-type="bibr" rid="bib39">Kieper and Jameson, 1999</xref>; <xref ref-type="bibr" rid="bib78">Tanchot, 1997</xref>] and γ-chain cytokines such as IL-7 and IL-15 [<xref ref-type="bibr" rid="bib69">Schluns et al., 2002</xref>; <xref ref-type="bibr" rid="bib68">Schluns et al., 2000</xref>; <xref ref-type="bibr" rid="bib25">Goldrath et al., 2004</xref>; <xref ref-type="bibr" rid="bib77">Tan et al., 2001</xref>]). However, as they grow, cells compete for access to these resources, limiting clonal expansion (<xref ref-type="bibr" rid="bib37">Jameson, 2002</xref>) such that logistic growth models are appropriate (<xref ref-type="bibr" rid="bib49">Mehr and Perelson, 1997</xref>).</p><p>In our mathematical model, transplanted HSPCs <italic>T</italic> home to the bone marrow at a rate <italic>k<sub>e</sub></italic>. We assumed a single-cell compartment for T cell progenitors in the bone marrow (BM)/thymus represented by variable <italic>P</italic>. We assumed that <italic>P</italic> renew logistically with maximum rate <italic>r<sub>p</sub></italic>, differentiate into naïve CD4<sup>+</sup> and CD8<sup>+</sup> T cells at rates <italic>λ<sub>f</sub></italic> and <italic>λ<sub>e</sub></italic>, respectively, or are cleared at rate <italic>d<sub>p</sub></italic> (<xref ref-type="bibr" rid="bib75">Stiehl and Marciniak-Czochra, 2011</xref>; <xref ref-type="bibr" rid="bib74">Stiehl et al., 2014</xref>; <xref ref-type="bibr" rid="bib76">Stiehl and Marciniak-Czochra, 2017</xref>). We assumed two CD4<sup>+</sup> T cell compartments: SHIV-non-susceptible, i.e. CD4<sup>+</sup> T cells that do not express CCR5 (CD4<sup>+</sup>CCR5<sup>-</sup> T cells) <italic>N</italic>, and a SHIV-susceptible compartment, <italic>S</italic> (CD4<sup>+</sup>CCR5<sup>+</sup> T cells). Only the <italic>N</italic> compartment includes CD4<sup>+</sup> naïve cells migrating from the thymus (<xref ref-type="bibr" rid="bib5">Bleul et al., 1997</xref>; <xref ref-type="bibr" rid="bib84">Zaitseva et al., 1998</xref>; <xref ref-type="bibr" rid="bib3">Berkowitz et al., 1998</xref>) at an input rate <italic>λ<sub>f</sub>P</italic> cells per day (<xref ref-type="bibr" rid="bib20">Douek et al., 2000</xref>; <xref ref-type="bibr" rid="bib48">McCune, 1997</xref>). <italic>N</italic> cells grow with maximum rate <italic>r<sub>n</sub></italic>, upregulate CCR5 (<italic>27</italic>) at rate <italic>λ<sub>n</sub></italic>, and are cleared from the periphery at rate <italic>d<sub>n</sub></italic>. The <italic>S</italic> compartment does not have a thymic input but can grow with maximum division rate <italic>r<sub>s</sub></italic>, downregulate CCR5 (<italic>27</italic>) at a rate <italic>λ<sub>s</sub></italic>, and are cleared at rate <italic>d<sub>s</sub></italic>. We model CD8<sup>+</sup> T cell reconstitution assuming a compartment for naïve and central memory cells, <italic>M</italic>, and a compartment for the effector memory subset, <italic>E</italic>. We assumed that <italic>M</italic> cells have thymic input of <italic>λ<sub>e</sub>P</italic> cells per day, grow logistically with maximum division rate <italic>r<sub>m</sub></italic>, differentiate to effector memory at rate <italic>λ<sub>m</sub></italic>, and are cleared at rate <italic>d<sub>m</sub></italic>. The <italic>E</italic> compartment grows with maximum division rate <italic>r<sub>e</sub></italic> and is cleared at rate <italic>d<sub>e</sub></italic>. We added variables <italic>T<sub>p</sub></italic>, <italic>P<sub>p</sub></italic>, <italic>N<sub>p1</sub></italic> and <italic>N<sub>p2</sub></italic>, representing CCR5 gene-modified- transplanted HSPCs, T cell progenitor cells in BM/thymus, and blood CD4<sup>+</sup>CCR5<sup>-</sup> T cells with CD4<sup>+</sup>CCR5<sup>-</sup> and CD4<sup>+</sup>CCR5<sup>+</sup> kinetics, respectively. These compartments have the same structure as <italic>T</italic>, <italic>P</italic>, <italic>N</italic> and <italic>S</italic>, but with two differences. First, the value of <italic>T<sub>p</sub></italic> at transplantation is a fraction <italic>f<sub>p</sub></italic> of the total number of infused cells. Second, the <italic>N<sub>p1</sub></italic> cell compartment do not upregulate CCR5 when transitioning to <italic>N<sub>p2</sub></italic>. We model the competition of CD4<sup>+</sup> and CD8<sup>+</sup> T cells for resources that allow cell division using a logistic equation that depends on the difference between the total number of competing cells, i.e. <italic>A</italic> = <italic>N<sub>p1</sub>+N<sub>p2</sub>+N+S+M+E</italic>, and a carrying capacity <italic>K</italic> (<xref ref-type="bibr" rid="bib37">Jameson, 2002</xref>). Under these assumptions we constructed the following model form:<disp-formula id="equ2"><label>(2)</label><mml:math id="m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtable columnalign="left left" columnspacing="1em" rowspacing="4pt"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>T</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>A</mml:mi><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>A</mml:mi><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:msub><mml:mi/><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>A</mml:mi><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>T</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>T</mml:mi><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>A</mml:mi><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>P</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>A</mml:mi><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mi>S</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mi>s</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>A</mml:mi><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>S</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mi>N</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mrow><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:msub><mml:mi/><mml:mi>m</mml:mi></mml:msub></mml:mrow></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>A</mml:mi><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>M</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>A</mml:mi><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>E</mml:mi></mml:mtd></mml:mtr></mml:mtable><mml:mo>,</mml:mo></mml:mrow></mml:mstyle></mml:math></disp-formula>where <inline-formula><mml:math id="inf124"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf125"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf126"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf127"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf128"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, as well as <inline-formula><mml:math id="inf129"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>w</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>K</mml:mi><mml:mfrac><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>w</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula> for each model variable <inline-formula><mml:math id="inf130"><mml:mrow><mml:mi>w</mml:mi><mml:mo>∈</mml:mo><mml:mrow><mml:mo>{</mml:mo> <mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>e</mml:mi></mml:mrow> <mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>. We did this re-parameterization to have compound parameters that were identifiable.</p><p>When simulating the model, we assumed <inline-formula><mml:math id="inf131"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> as the time of transplantation. For the transplant groups the system is in a transient stage due to conditioning (TBI) at <inline-formula><mml:math id="inf132"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>, therefore initial values cannot be obtained from steady state equations. Transplantation is modeled as <inline-formula><mml:math id="inf133"><mml:mrow><mml:mi>T</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf134"><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mi>D</mml:mi></mml:mrow></mml:math></inline-formula>. For the control group we used <inline-formula><mml:math id="inf135"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> at a similar time relative to the transplant groups. Since the control group did not have any transplantation or TBI, we assumed <inline-formula><mml:math id="inf136"><mml:mrow><mml:mi>T</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>. Other initial values were calculated assuming steady state: <inline-formula><mml:math id="inf137"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msub><mml:mi>q</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:msub><mml:mi>q</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:msub><mml:mi>q</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>q</mml:mi><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="inf138"><mml:mrow><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>q</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:msub><mml:mi>q</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:msub><mml:mi>q</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>q</mml:mi><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="inf139"><mml:mrow><mml:mi>S</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:msub><mml:mi>q</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:msub><mml:mi>q</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>q</mml:mi><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="inf140"><mml:mrow><mml:mi>M</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msub><mml:mi>q</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:msub><mml:mi>q</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>q</mml:mi><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf141"><mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:msub><mml:mi>q</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>q</mml:mi><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula>. Here <inline-formula><mml:math id="inf142"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mtext> </mml:mtext></mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf143"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mtext> </mml:mtext></mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf144"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mtext> </mml:mtext></mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf145"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mtext> </mml:mtext></mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>. A parsimonious, curated version of this model was selected from a series of models with varying mechanistic and statistical complexity (<xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref>).</p></sec><sec id="s4-4"><title>Mathematical modeling of SHIV infection and T cell response dynamics</title><p>We next adapted the curated T cell reconstitution model by combining several adaptations of the canonical model of viral dynamics (<xref ref-type="bibr" rid="bib64">Reeves et al., 2017</xref>; <xref ref-type="bibr" rid="bib56">Perelson, 2002</xref>; <xref ref-type="bibr" rid="bib55">Perelson et al., 1997</xref>; <xref ref-type="bibr" rid="bib34">Hill et al., 2018</xref>; <xref ref-type="bibr" rid="bib6">Borducchi et al., 2016</xref>; <xref ref-type="bibr" rid="bib16">De Boer, 2007</xref>; <xref ref-type="bibr" rid="bib82">Wodarz and Nowak, 1999</xref>; <xref ref-type="bibr" rid="bib54">Pandit and de Boer, 2016</xref>). Here, virus <italic>V</italic> infects only CD4<sup>+</sup>CCR5<sup>+</sup> T cells (<xref ref-type="bibr" rid="bib35">Ho et al., 2009</xref>) <italic>S</italic> at rate <italic>β</italic>. We modeled ART by reducing the infection rate to zero. A fraction <italic>τ</italic> of the infected cells produce virus, <italic>I<sub>p</sub></italic>, and the other fraction become unproductively infected, <italic>I<sub>u</sub></italic> (<xref ref-type="bibr" rid="bib64">Reeves et al., 2017</xref>; <xref ref-type="bibr" rid="bib17">Doitsh et al., 2010</xref>; <xref ref-type="bibr" rid="bib47">Matrajt et al., 2014</xref>). <italic>I<sub>P</sub></italic> cells arise only from activation of a persistent set of latently infected cells at rate <inline-formula><mml:math id="inf146"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>ξ</mml:mi><mml:mrow><mml:mover><mml:mi>L</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>. We modeled ATI by assuming infection <italic>β</italic> is greater than zero after some delay following ATI. We approximate this delay as the sum of the time of ART to washout (~3 days) and the time of successful activation (<inline-formula><mml:math id="inf147"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>) of a steady set of latently infected cells. For simplicity, we assumed that <inline-formula><mml:math id="inf148"><mml:mrow><mml:mi>ξ</mml:mi><mml:mover accent="true"><mml:mi>L</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula> and assumed that <inline-formula><mml:math id="inf149"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> has lognormal distribution among the animal population with high variance (<xref ref-type="bibr" rid="bib14">Conway et al., 2019</xref>; <xref ref-type="bibr" rid="bib33">Hill et al., 2014</xref>; <xref ref-type="bibr" rid="bib61">Prague et al., 2019</xref>). All infected cells die at rate <italic>δ<sub>I</sub></italic> (<xref ref-type="bibr" rid="bib64">Reeves et al., 2017</xref>). <italic>I<sub>P</sub></italic> cells produce virus at a rate <italic>π</italic> per cell, that is cleared at rate <italic>γ</italic>. CD8<sup>+</sup> <italic>M</italic> cells proliferate in the presence of infection with maximum rate <italic>ω<sub>8</sub></italic>. A fraction <italic>f</italic> of these cells become SHIV-specific CD8<sup>+</sup> effector T cells, <italic>E<sub>h</sub></italic>, that are removed at a rate <italic>d<sub>h</sub></italic> (<xref ref-type="bibr" rid="bib16">De Boer, 2007</xref>; <xref ref-type="bibr" rid="bib82">Wodarz and Nowak, 1999</xref>; <xref ref-type="bibr" rid="bib81">Wodarz et al., 2000</xref>). These effector cells may reduce virus production (<italic>π</italic>) or increase infected cell clearance (<italic>δ<sub>I</sub></italic>) by 1/ (1+<italic>θE<sub>h</sub></italic>) or by (1+<italic>κE<sub>h</sub></italic>), respectively (<xref ref-type="bibr" rid="bib22">Elemans et al., 2011</xref>; <xref ref-type="bibr" rid="bib40">Klatt et al., 2010</xref>; <xref ref-type="bibr" rid="bib83">Wong et al., 2010</xref>; <xref ref-type="bibr" rid="bib6">Borducchi et al., 2016</xref>; <xref ref-type="bibr" rid="bib10">Cardozo et al., 2018</xref>). We assumed that non-susceptible CD4<sup>+</sup> T cells may upregulate CCR5 and replenish the susceptible pool during infection (<xref ref-type="bibr" rid="bib50">Okoye et al., 2007</xref>; <xref ref-type="bibr" rid="bib51">Okoye et al., 2012</xref>; <xref ref-type="bibr" rid="bib52">Okoye and Picker, 2013</xref>) with rate <italic>ω<sub>4</sub></italic>. For cell growth the total number of competing cells is given by <italic>A</italic> =<italic>N<sub>p1</sub>+N<sub>p2</sub>+N+S+I<sub>p</sub>+I<sub>u</sub>+M+E+E<sub>h</sub></italic>. The model in <xref ref-type="disp-formula" rid="equ2">Equation 2</xref> is modified to include:<disp-formula id="equ3"><label>(3)</label><mml:math id="m3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtable columnalign="left left" columnspacing="1em" rowspacing="4pt"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mi>n</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>A</mml:mi><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mi>S</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>ω</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mfrac><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mfrac><mml:mi>N</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mi>s</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>A</mml:mi><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>S</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mi>N</mml:mi><mml:mo>−</mml:mo><mml:mi>β</mml:mi><mml:mi>V</mml:mi><mml:mi>S</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>ω</mml:mi><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:mfrac><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mfrac><mml:mi>N</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>τ</mml:mi><mml:mi>β</mml:mi><mml:mi>V</mml:mi><mml:mi>S</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mrow><mml:mi>I</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>κ</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>ξ</mml:mi><mml:mrow><mml:mover><mml:mi>L</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mi>β</mml:mi><mml:mi>V</mml:mi><mml:mi>S</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mrow><mml:mi>I</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>κ</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>θ</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mi>π</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>γ</mml:mi><mml:mi>V</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>A</mml:mi><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>ω</mml:mi><mml:mrow><mml:mn>8</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>f</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mfrac><mml:mi>M</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>ω</mml:mi><mml:mrow><mml:mn>8</mml:mn></mml:mrow></mml:msub><mml:mi>f</mml:mi><mml:mfrac><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mfrac><mml:mi>M</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>When simulating this model, we assume <inline-formula><mml:math id="inf150"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula> as the moment of SHIV challenge, and <inline-formula><mml:math id="inf151"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mi>x</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> as the moment of transplantation after challenge. We modeled conditioning by: (1) adding a term <inline-formula><mml:math id="inf152"><mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mi>C</mml:mi></mml:mrow></mml:math></inline-formula> in all blood cell compartments <inline-formula><mml:math id="inf153"><mml:mrow><mml:mi>C</mml:mi><mml:mo>∈</mml:mo><mml:mrow><mml:mo>{</mml:mo> <mml:mrow><mml:mi>N</mml:mi><mml:mo>,</mml:mo><mml:mi>S</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>u</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mi>M</mml:mi><mml:mo>,</mml:mo><mml:mi>E</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mi>h</mml:mi></mml:msub></mml:mrow> <mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and (2) the term <inline-formula><mml:math id="inf154"><mml:mrow><mml:mo> </mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mi>H</mml:mi></mml:msub><mml:mi>P</mml:mi></mml:mrow></mml:math></inline-formula> for the HSPC compartment <inline-formula><mml:math id="inf155"><mml:mi>P</mml:mi></mml:math></inline-formula>. <inline-formula><mml:math id="inf156"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf157"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>H</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> are different than zero only during the 2 days before transplant (<inline-formula><mml:math id="inf158"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mi>x</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mo>≤</mml:mo><mml:mo> </mml:mo><mml:mi>t</mml:mi><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>x</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>). Transplantation is modeled as an input only when <inline-formula><mml:math id="inf159"><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>x</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> to cell compartments <inline-formula><mml:math id="inf160"><mml:mi>T</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="inf161"><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> with amounts <inline-formula><mml:math id="inf162"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf163"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mi>D</mml:mi></mml:mrow></mml:math></inline-formula>, respectively. A parsimonious version of this model was selected from a series of models with varying mechanistic and statistical complexity (<xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref>).</p></sec><sec id="s4-5"><title>Nonlinear mixed-effects modeling</title><p>To fit our models (<xref ref-type="disp-formula" rid="equ2 equ3">Equations 2, 3)</xref> to the transplant data, we used a nonlinear mixed-effects modeling approach (<xref ref-type="bibr" rid="bib43">Lavielle, 2014</xref>). Within this approach, we modeled a state variable vector <inline-formula><mml:math id="inf164"><mml:mi>v</mml:mi></mml:math></inline-formula> with observations at time <inline-formula><mml:math id="inf165"><mml:mrow><mml:mo> </mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula> for each animal <inline-formula><mml:math id="inf166"><mml:mi>j</mml:mi></mml:math></inline-formula> as <inline-formula><mml:math id="inf167"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:msub><mml:mi>g</mml:mi><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">Ψ</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>ϵ</mml:mi><mml:mrow><mml:mi>v</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>. Here, <inline-formula><mml:math id="inf168"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>v</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> describes the solution of the nonlinear models in <xref ref-type="disp-formula" rid="equ2">Equations 2</xref> or 3 for the state variable vector <inline-formula><mml:math id="inf169"><mml:mi>v</mml:mi></mml:math></inline-formula> at observation time <inline-formula><mml:math id="inf170"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> with animal-specific parameter set <inline-formula><mml:math id="inf171"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">Ψ</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>. The distribution of measurement noise is assumed as <inline-formula><mml:math id="inf172"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mrow><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mo>∼</mml:mo><mml:mrow><mml:mi mathvariant="script">𝒩</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p><p>In the mixed-effects model, it is assumed that for an animal <inline-formula><mml:math id="inf173"><mml:mi>j</mml:mi></mml:math></inline-formula> each single parameter <inline-formula><mml:math id="inf174"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>ψ</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">Ψ</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is drawn from a probability distribution across the population. This distribution includes the fixed effects <inline-formula><mml:math id="inf175"><mml:mover accent="true"><mml:mi>ψ</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:math></inline-formula> representing the median value over the population, and the random effects <inline-formula><mml:math id="inf176"><mml:mrow><mml:msub><mml:mi>η</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> representing its variability in the population, assumed to be normally distributed with standard deviation <inline-formula><mml:math id="inf177"><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mi>ψ</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, that is <inline-formula><mml:math id="inf178"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>∼</mml:mo><mml:mrow><mml:mi mathvariant="script">𝒩</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>. We assumed that the random effects of the parameters <inline-formula><mml:math id="inf179"><mml:mrow><mml:mo> </mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> might not be independent. In that case, the vector of random effects <inline-formula><mml:math id="inf180"><mml:mrow><mml:msub><mml:mi>η</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo> </mml:mo></mml:mrow></mml:math></inline-formula> follows a multinormal distribution: <inline-formula><mml:math id="inf181"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>η</mml:mi><mml:mo>∼</mml:mo><mml:mrow><mml:mi mathvariant="script">𝒩</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>, being <inline-formula><mml:math id="inf182"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> the variance-covariance matrix based on the values <inline-formula><mml:math id="inf183"><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mi>ψ</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and correlations between the individual parameters in <inline-formula><mml:math id="inf184"><mml:mi>η</mml:mi></mml:math></inline-formula>.</p><p>We fit each model to all data points from all animals simultaneously using a maximum likelihood approach. We assumed that individual observations of each state variable <inline-formula><mml:math id="inf185"><mml:mrow><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> for each animal <inline-formula><mml:math id="inf186"><mml:mi>j</mml:mi></mml:math></inline-formula> at each time point <inline-formula><mml:math id="inf187"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> are independent. For each model, we obtained the Maximum Likelihood Estimation (MLE) of the standard deviation of the measurement error for the observations <inline-formula><mml:math id="inf188"><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mi>v</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, and each parameter fixed effects <inline-formula><mml:math id="inf189"><mml:mover accent="true"><mml:mi>ψ</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:math></inline-formula> and standard deviation of the random effects <inline-formula><mml:math id="inf190"><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mi>ψ</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> (or elements in matrix <inline-formula><mml:math id="inf191"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> when applicable) using the Stochastic Approximation of the Expectation Maximization (SAEM) algorithm embedded in the Monolix software (<ext-link ext-link-type="uri" xlink:href="http://www.lixoft.eu">http://www.lixoft.eu</ext-link>).</p></sec><sec id="s4-6"><title>Fitting T cell reconstitution before ATI</title><p>We first fit the observed blood T cell kinetics after HSPC transplantation and before analytical treatment interruption (ATI) using the model in <xref ref-type="disp-formula" rid="equ2">Equation 2</xref>. During this procedure, we defined the vector <inline-formula><mml:math id="inf192"><mml:mrow><mml:msup><mml:mi>v</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> to model the log<sub>10</sub> of the observed blood CD4<sup>+</sup>CCR5<sup>-</sup>, CD4<sup>+</sup>CCR5<sup>+</sup>, total CD8<sup>+</sup>, CD8<sup>+</sup> T<sub>N</sub> + T<sub>CM</sub>, and CD8<sup>+</sup> T<sub>EM</sub> cell counts which are represented in <xref ref-type="disp-formula" rid="equ2">Equation 2</xref> by the variables <inline-formula><mml:math id="inf193"><mml:mrow><mml:mrow><mml:mo>{</mml:mo> <mml:mrow><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>S</mml:mi><mml:mo>,</mml:mo><mml:mi>C</mml:mi><mml:mo>,</mml:mo><mml:mi>M</mml:mi><mml:mo>,</mml:mo><mml:mi>E</mml:mi></mml:mrow> <mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, respectively with <inline-formula><mml:math id="inf194"><mml:mrow><mml:mi>C</mml:mi><mml:mo>=</mml:mo><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:mi>E</mml:mi></mml:mrow></mml:math></inline-formula> and solution <inline-formula><mml:math id="inf195"><mml:mrow><mml:msup><mml:mi>f</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>.</p><p>We defined the statistical form of each parameter in <inline-formula><mml:math id="inf196"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">Ψ</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula> in the following form: parameters <inline-formula><mml:math id="inf197"><mml:mrow><mml:msubsup><mml:mover accent="true"><mml:mi>r</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>p</mml:mi><mml:mi>j</mml:mi></mml:msubsup><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:msubsup><mml:mover accent="true"><mml:mi>r</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>m</mml:mi><mml:mi>j</mml:mi></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>r</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>e</mml:mi><mml:mi>j</mml:mi></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>λ</mml:mi><mml:mi>f</mml:mi><mml:mi>j</mml:mi></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>λ</mml:mi><mml:mi>e</mml:mi><mml:mi>j</mml:mi></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>λ</mml:mi><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>λ</mml:mi><mml:mi>s</mml:mi><mml:mi>j</mml:mi></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>λ</mml:mi><mml:mi>m</mml:mi><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> were modeled as <inline-formula><mml:math id="inf198"><mml:mrow><mml:msub><mml:mi>ψ</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mover accent="true"><mml:mi>ψ</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>; parameter <inline-formula><mml:math id="inf199"><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mi>p</mml:mi><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> was modeled as <inline-formula><mml:math id="inf200"><mml:mrow><mml:msub><mml:mi>ψ</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>ψ</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mo>+</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>; <inline-formula><mml:math id="inf201"><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>K</mml:mi><mml:mi>s</mml:mi><mml:mi>j</mml:mi></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>K</mml:mi><mml:mi>m</mml:mi><mml:mi>j</mml:mi></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>K</mml:mi><mml:mi>e</mml:mi><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> were modeled as <inline-formula><mml:math id="inf202"><mml:mrow><mml:msub><mml:mi>ψ</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mi>p</mml:mi><mml:mi>j</mml:mi></mml:msubsup><mml:mo>−</mml:mo><mml:mover accent="true"><mml:mi>ψ</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>; and initial values in the transplant group: <inline-formula><mml:math id="inf203"><mml:mrow><mml:msup><mml:mi>N</mml:mi><mml:mi>j</mml:mi></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:msup><mml:mi>S</mml:mi><mml:mi>j</mml:mi></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:msup><mml:mi>M</mml:mi><mml:mi>j</mml:mi></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo> </mml:mo></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf204"><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mi>j</mml:mi></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> had the model <inline-formula><mml:math id="inf205"><mml:mrow><mml:msub><mml:mi>ψ</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>ψ</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mo>+</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:msup><mml:mo>.</mml:mo></mml:mrow></mml:math></inline-formula> We explored the possibility that <inline-formula><mml:math id="inf206"><mml:mrow><mml:msub><mml:mi>r</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>, in that case we assumed <inline-formula><mml:math id="inf207"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>d</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>λ</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mrow><mml:mover><mml:mi>ψ</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>. We fixed the HSPC homing rate <italic>k<sub>e</sub></italic> = 1/day (<xref ref-type="bibr" rid="bib42">Lapidot et al., 2005</xref>; <xref ref-type="bibr" rid="bib13">Chute, 2006</xref>), and <inline-formula><mml:math id="inf208"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf209"><mml:mi>D</mml:mi></mml:math></inline-formula> as described in <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>. Since at <inline-formula><mml:math id="inf210"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> the system is in a transient stage due to conditioning (TBI), we estimated blood cell concentrations at <inline-formula><mml:math id="inf211"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>, but fixed the number of HSPCs that remained in the BM/thymus <inline-formula><mml:math id="inf212"><mml:mrow><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> to <inline-formula><mml:math id="inf213"><mml:mrow><mml:mn>6</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mn>6</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> based on the estimated minimum number of infused HSPCs needed for engraftment in the same animal model (<xref ref-type="bibr" rid="bib62">Radtke et al., 2017</xref>).</p><p>We fit instances of models with varying statistical and mechanistic complexity in <xref ref-type="disp-formula" rid="equ2">Equation 2</xref> to blood T cell counts during transplant and before ATI (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) assuming that one or multiple mechanisms are absent, or that certain mechanisms have equal kinetics (<xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref> includes all 24 competing models with the different statistical assumptions).</p></sec><sec id="s4-7"><title>Fitting T cell and viral load dynamics before and after ATI</title><p>Next, we fit the model in <xref ref-type="disp-formula" rid="equ2 equ3">Equations 2-3</xref> to the pre- and post-ATI blood T cell counts and plasma viral loads (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Here, we defined <inline-formula><mml:math id="inf214"><mml:mrow><mml:msup><mml:mi>v</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> for variables <inline-formula><mml:math id="inf215"><mml:mrow><mml:mrow><mml:mo>{</mml:mo> <mml:mrow><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>R</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mn>8</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mi>M</mml:mi><mml:mo>,</mml:mo><mml:mi>E</mml:mi><mml:mo>,</mml:mo><mml:mi>V</mml:mi></mml:mrow> <mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> with <inline-formula><mml:math id="inf216"><mml:mi>V</mml:mi></mml:math></inline-formula> indicating the observed plasma viral load,<inline-formula><mml:math id="inf217"><mml:mrow><mml:mo> </mml:mo><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> indicating the observed blood CD4<sup>+</sup>CCR5<sup>-</sup> T cell concentration, <inline-formula><mml:math id="inf218"><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mi>S</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>u</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> the observed blood CD4<sup>+</sup>CCR5<sup>+</sup> T cell concentration, <inline-formula><mml:math id="inf219"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mn>8</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> the total CD8<sup>+</sup> T cell concentration, <inline-formula><mml:math id="inf220"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> the total CD4<sup>+</sup> T cell concentration and the others state-variables as specified for <inline-formula><mml:math id="inf221"><mml:mrow><mml:msup><mml:mi>v</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>. We included <inline-formula><mml:math id="inf222"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mn>4</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> because we had total CD4<sup>+</sup> T cell counts, but CD4<sup>+</sup> T subset counts during the primary infection stage were not available in many of the animals. For this model, we defined the parameter set <inline-formula><mml:math id="inf223"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">Ψ</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula> by adding to the parameters in the previous section the parameters relative to virus dynamics (i.e. <inline-formula><mml:math id="inf224"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">Ψ</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">Ψ</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mi>κ</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mi>β</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mi>π</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>ω</mml:mi><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>ω</mml:mi><mml:mrow><mml:mn>8</mml:mn></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mi>h</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>t</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> but fixing the values in <inline-formula><mml:math id="inf225"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">Ψ</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula> to the MLE values using <xref ref-type="supplementary-material" rid="fig3sdata3">Figure 3—source data 3</xref>). For parameters <inline-formula><mml:math id="inf226"><mml:mrow><mml:msup><mml:mi>κ</mml:mi><mml:mi>j</mml:mi></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mi>j</mml:mi></mml:msup><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:msup><mml:mi>β</mml:mi><mml:mi>j</mml:mi></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mi>π</mml:mi><mml:mi>j</mml:mi></mml:msup><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:msubsup><mml:mi>ω</mml:mi><mml:mn>4</mml:mn><mml:mi>j</mml:mi></mml:msubsup><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:msubsup><mml:mi>ω</mml:mi><mml:mn>8</mml:mn><mml:mi>j</mml:mi></mml:msubsup><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mi>j</mml:mi></mml:msubsup><mml:mtext> </mml:mtext></mml:mrow></mml:math></inline-formula>, we used a model with form <inline-formula><mml:math id="inf227"><mml:mrow><mml:msub><mml:mi>ψ</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>ψ</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mo>+</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, and for <inline-formula><mml:math id="inf228"><mml:mrow><mml:msubsup><mml:mi>d</mml:mi><mml:mi>h</mml:mi><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf229"><mml:mrow><mml:msubsup><mml:mi>t</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>a</mml:mi></mml:mrow><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> we used <inline-formula><mml:math id="inf230"><mml:mrow><mml:msub><mml:mi>ψ</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mover accent="true"><mml:mi>ψ</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>. We included the possibility that immunity might be different at ATI compared to pre-ART by assuming the forms <inline-formula><mml:math id="inf231"><mml:mrow><mml:msubsup><mml:mi>ψ</mml:mi><mml:mrow/><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi><mml:mi>T</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>ψ</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mo>+</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>ς</mml:mi><mml:mrow><mml:mi>ψ</mml:mi><mml:mo>,</mml:mo><mml:mtext>ATI</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> for <inline-formula><mml:math id="inf232"><mml:mrow><mml:msubsup><mml:mi>ω</mml:mi><mml:mn>8</mml:mn><mml:mi>j</mml:mi></mml:msubsup><mml:mo> </mml:mo></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf233"><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula>, and <inline-formula><mml:math id="inf234"><mml:mrow><mml:msubsup><mml:mi>ψ</mml:mi><mml:mrow/><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi><mml:mi>T</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mover accent="true"><mml:mi>ψ</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>ς</mml:mi><mml:mrow><mml:mi>ψ</mml:mi><mml:mo>,</mml:mo><mml:mtext>ATI</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> for <inline-formula><mml:math id="inf235"><mml:mrow><mml:msubsup><mml:mi>d</mml:mi><mml:mi>h</mml:mi><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> during ATI. We evaluated single or combination of mechanistic hypotheses along with different statistical assumptions as listed in <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref> using AIC. <inline-formula><mml:math id="inf236"><mml:mrow><mml:mi>V</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> was fixed to a small value below the limit of detection, and <inline-formula><mml:math id="inf237"><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf238"><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>u</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> were calculated as <inline-formula><mml:math id="inf239"><mml:mrow><mml:mi>τ</mml:mi><mml:mi>c</mml:mi><mml:mi>V</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mi>π</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf240"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>τ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>c</mml:mi><mml:mi>V</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mi>π</mml:mi></mml:mrow></mml:math></inline-formula>, respectively. We fixed the following parameters: <inline-formula><mml:math id="inf241"><mml:mrow><mml:mi>γ</mml:mi><mml:mo>=</mml:mo><mml:mn>23</mml:mn></mml:mrow></mml:math></inline-formula>/day (<xref ref-type="bibr" rid="bib63">Ramratnam et al., 1999</xref>), <inline-formula><mml:math id="inf242"><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi>I</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>/day (<xref ref-type="bibr" rid="bib46">Markowitz et al., 2003</xref>; <xref ref-type="bibr" rid="bib9">Cardozo et al., 2017</xref>), <inline-formula><mml:math id="inf243"><mml:mrow><mml:mi>τ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula> (<xref ref-type="bibr" rid="bib17">Doitsh et al., 2010</xref>), and <inline-formula><mml:math id="inf244"><mml:mrow><mml:mi>f</mml:mi><mml:mo>=</mml:mo></mml:mrow></mml:math></inline-formula> 0.9 (<xref ref-type="bibr" rid="bib6">Borducchi et al., 2016</xref>). The value of <inline-formula><mml:math id="inf245"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>h</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> was constrained to obtain a value of the HSPCs after conditioning <inline-formula><mml:math id="inf246"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mi>x</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>6</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mn>6</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> (<xref ref-type="bibr" rid="bib62">Radtke et al., 2017</xref>). We fixed values of <inline-formula><mml:math id="inf247"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mi>x</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="inf248"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf249"><mml:mi>D</mml:mi></mml:math></inline-formula> as described in <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>.</p><p>We fit several instances of the model in <xref ref-type="disp-formula" rid="equ3">Equation 3</xref> to pre- and post-ATI blood T cell counts and plasma viral loads (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) using the best model obtained for <xref ref-type="disp-formula" rid="equ2">Equation 2</xref> (<xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref> includes all four competing models and respective statistical assumptions). At the time of SHIV infection, values for the cell compartments were calculated from steady state equations with the same form as for the group without transplantation (‘control’) in the previous section.</p></sec><sec id="s4-8"><title>Model selection</title><p>To determine the best and most parsimonious model among the instances, we computed the log-likelihood (log <italic>L</italic>) and the Akaike Information Criteria (AIC=-2log <italic>L</italic>+2 m, where <italic>m</italic> is the number of parameters estimated) (<xref ref-type="bibr" rid="bib8">Burnham et al., 2002</xref>). We assumed a model has similar support from the data if the difference between its AIC and the best model (lowest) AIC is less than two (<xref ref-type="bibr" rid="bib8">Burnham et al., 2002</xref>).</p></sec><sec id="s4-9"><title>Effective reproductive ratio when <inline-formula><mml:math id="inf250"><mml:mrow><mml:msub><mml:mi>r</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf251"><mml:mrow><mml:mi>κ</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula></title><p>We calculated an approximate effective reproductive ratio <inline-formula><mml:math id="inf252"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> for our model (<xref ref-type="disp-formula" rid="equ2 equ3">Equations 2, 3)</xref> by computing the average number of offspring produced by one productively infected cell <inline-formula><mml:math id="inf253"><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> at ATI assuming all cell compartments have reached steady state after transplantation during ART. This number is the product of the average lifespan of one <inline-formula><mml:math id="inf254"><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, the virus production rate by this latently infected cell, the lifespan of produced virions from this cell, the rate at which each virion infects the pool of susceptible cells at steady state, the fraction of these infections that become productive and the reduction of virus production, cell infection, and cell death by SHIV-specific immune cells at ATI. Using this approach, we obtain that <inline-formula><mml:math id="inf255"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>τ</mml:mi><mml:mi>β</mml:mi><mml:mover accent="true"><mml:mi>S</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>γ</mml:mi><mml:msub><mml:mi>δ</mml:mi><mml:mi>I</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>θ</mml:mi><mml:msub><mml:mover accent="true"><mml:mi>E</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi>h</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula>, with <inline-formula><mml:math id="inf256"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mover><mml:mi>S</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mo>≈</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mover><mml:mi>P</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>d</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf257"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>E</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:mo>≈</mml:mo><mml:mfrac><mml:mrow><mml:mi>f</mml:mi><mml:msub><mml:mi>ω</mml:mi><mml:mrow><mml:mn>8</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>δ</mml:mi><mml:mrow><mml:mi>I</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula> the steady state values of variables <inline-formula><mml:math id="inf258"><mml:mi>S</mml:mi></mml:math></inline-formula> (SHIV-susceptible cells) and <inline-formula><mml:math id="inf259"><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mi>h</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> (SHIV-specific effector cells) during ART, with <inline-formula><mml:math id="inf260"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>a</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>d</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>d</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula><inline-formula><mml:math id="inf261"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>f</mml:mi><mml:msub><mml:mi>ω</mml:mi><mml:mrow><mml:mn>8</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>δ</mml:mi><mml:mrow><mml:mi>I</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula>. By assuming that the total amount of infused cells (dose <inline-formula><mml:math id="inf262"><mml:mi>D</mml:mi></mml:math></inline-formula> and fraction of CCR5-editing <inline-formula><mml:math id="inf263"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>) home to the BM/Thymus rapidly, and that the amount of remaining HSPCs after TBI and immediately before transplant is <inline-formula><mml:math id="inf264"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mi>x</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, the approximate steady state for <inline-formula><mml:math id="inf265"><mml:mi>P</mml:mi></mml:math></inline-formula> is <inline-formula><mml:math id="inf266"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mover><mml:mi>P</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mo>≈</mml:mo><mml:mfrac><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mi>a</mml:mi></mml:mfrac><mml:mo>⋅</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>D</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mi>a</mml:mi></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>. Together this gives the following expression for the effective reproductive ratio:<disp-formula id="equ4"><label>(4)</label><mml:math id="m4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mrow><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>τ</mml:mi><mml:mi>β</mml:mi><mml:mi>π</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>γ</mml:mi><mml:msub><mml:mi>δ</mml:mi><mml:mrow><mml:mi>I</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>d</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mover><mml:mi>r</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>θ</mml:mi><mml:msub><mml:mrow><mml:mover><mml:mi>E</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>Here, <inline-formula><mml:math id="inf267"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> then represents the effective reproductive ratio during transplant in the absence of gene-editing when cells have reached steady state.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>This study was supported by grants from the National Institutes of Health, National Institute of Allergy and Infectious Diseases (UM1 AI126623, R01 AI150500). ERD is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number KL2 TR002317. DBR is supported by a Washington Research Foundation postdoctoral fellowship, and a CFAR NIA P30 AI027757. NHP studies were supported by NIH P51 OD010425. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Washington Research Foundation.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>H.-P.K has served on advisory boards for Rocket Pharmaceuticals, Homology medicines and CSL for research unrelated to this manuscript.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Software, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing, Developed the mathematical models, wrote all code, performed all calculations and derivations, ran the models in Monolix and analyzed output data</p></fn><fn fn-type="con" id="con2"><p>Visualization, Methodology, Writing - review and editing, Development of mechanistic mathematical models</p></fn><fn fn-type="con" id="con3"><p>Data curation, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Methodology, Writing - review and editing, Development of mechanistic mathematical models</p></fn><fn fn-type="con" id="con5"><p>Methodology, Writing - review and editing, Contributed ideas and support for statistical models and analyses</p></fn><fn fn-type="con" id="con6"><p>Data curation, Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Supervision, Funding acquisition, Methodology, Writing - original draft, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: The data used in this work were collected in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The study protocol was approved by the Institutional Animal Care and Use Committees (IACUC) protocols (#3235-03) of the Fred Hutchinson Cancer Research Center and the University of Washington.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-57646-transrepform-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 2 to 7. Details of the source data for each figure are in the Transparent Reporting form.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allers</surname> <given-names>K</given-names></name><name><surname>Hütter</surname> <given-names>G</given-names></name><name><surname>Hofmann</surname> <given-names>J</given-names></name><name><surname>Loddenkemper</surname> <given-names>C</given-names></name><name><surname>Rieger</surname> <given-names>K</given-names></name><name><surname>Thiel</surname> <given-names>E</given-names></name><name><surname>Schneider</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation</article-title><source>Blood</source><volume>117</volume><fpage>2791</fpage><lpage>2799</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-09-309591</pub-id><pub-id pub-id-type="pmid">21148083</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bender</surname> <given-names>J</given-names></name><name><surname>Mitchell</surname> <given-names>T</given-names></name><name><surname>Kappler</surname> <given-names>J</given-names></name><name><surname>Marrack</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Cd4+ T cell division in irradiated mice requires peptides distinct from those responsible for thymic selection</article-title><source>Journal of Experimental Medicine</source><volume>190</volume><fpage>367</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1084/jem.190.3.367</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berkowitz</surname> <given-names>RD</given-names></name><name><surname>Beckerman</surname> <given-names>KP</given-names></name><name><surname>Schall</surname> <given-names>TJ</given-names></name><name><surname>McCune</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>CXCR4 and CCR5 expression delineates targets for HIV-1 disruption of T cell differentiation</article-title><source>Journal of Immunology</source><volume>161</volume><fpage>3702</fpage><lpage>3710</lpage></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blazek</surname> <given-names>D</given-names></name><name><surname>Teque</surname> <given-names>F</given-names></name><name><surname>Mackewicz</surname> <given-names>C</given-names></name><name><surname>Peterlin</surname> <given-names>M</given-names></name><name><surname>Levy</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The CD8+ cell non-cytotoxic antiviral response affects RNA polymerase II-mediated human immunodeficiency virus transcription in infected CD4+ cells</article-title><source>Journal of General Virology</source><volume>97</volume><fpage>220</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1099/jgv.0.000326</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bleul</surname> <given-names>CC</given-names></name><name><surname>Wu</surname> <given-names>L</given-names></name><name><surname>Hoxie</surname> <given-names>JA</given-names></name><name><surname>Springer</surname> <given-names>TA</given-names></name><name><surname>Mackay</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes</article-title><source>PNAS</source><volume>94</volume><fpage>1925</fpage><lpage>1930</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.5.1925</pub-id><pub-id pub-id-type="pmid">9050881</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borducchi</surname> <given-names>EN</given-names></name><name><surname>Cabral</surname> <given-names>C</given-names></name><name><surname>Stephenson</surname> <given-names>KE</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Abbink</surname> <given-names>P</given-names></name><name><surname>Ng'ang'a</surname> <given-names>D</given-names></name><name><surname>Nkolola</surname> <given-names>JP</given-names></name><name><surname>Brinkman</surname> <given-names>AL</given-names></name><name><surname>Peter</surname> <given-names>L</given-names></name><name><surname>Lee</surname> <given-names>BC</given-names></name><name><surname>Jimenez</surname> <given-names>J</given-names></name><name><surname>Jetton</surname> <given-names>D</given-names></name><name><surname>Mondesir</surname> <given-names>J</given-names></name><name><surname>Mojta</surname> <given-names>S</given-names></name><name><surname>Chandrashekar</surname> <given-names>A</given-names></name><name><surname>Molloy</surname> <given-names>K</given-names></name><name><surname>Alter</surname> <given-names>G</given-names></name><name><surname>Gerold</surname> <given-names>JM</given-names></name><name><surname>Hill</surname> <given-names>AL</given-names></name><name><surname>Lewis</surname> <given-names>MG</given-names></name><name><surname>Pau</surname> <given-names>MG</given-names></name><name><surname>Schuitemaker</surname> <given-names>H</given-names></name><name><surname>Hesselgesser</surname> <given-names>J</given-names></name><name><surname>Geleziunas</surname> <given-names>R</given-names></name><name><surname>Kim</surname> <given-names>JH</given-names></name><name><surname>Robb</surname> <given-names>ML</given-names></name><name><surname>Michael</surname> <given-names>NL</given-names></name><name><surname>Barouch</surname> <given-names>DH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys</article-title><source>Nature</source><volume>540</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1038/nature20583</pub-id><pub-id pub-id-type="pmid">27841870</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchholz</surname> <given-names>VR</given-names></name><name><surname>Flossdorf</surname> <given-names>M</given-names></name><name><surname>Hensel</surname> <given-names>I</given-names></name><name><surname>Kretschmer</surname> <given-names>L</given-names></name><name><surname>Weissbrich</surname> <given-names>B</given-names></name><name><surname>Gräf</surname> <given-names>P</given-names></name><name><surname>Verschoor</surname> <given-names>A</given-names></name><name><surname>Schiemann</surname> <given-names>M</given-names></name><name><surname>Höfer</surname> <given-names>T</given-names></name><name><surname>Busch</surname> <given-names>DH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Disparate individual fates compose robust CD8+ T cell immunity</article-title><source>Science</source><volume>340</volume><fpage>630</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1126/science.1235454</pub-id><pub-id pub-id-type="pmid">23493420</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Burnham</surname> <given-names>KP</given-names></name><name><surname>Anderson</surname> <given-names>DR</given-names></name><name><surname>Selection</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2002">2002</year><source> Model Selection and Multimodel Inference: </source><publisher-loc>New York</publisher-loc><publisher-name>Springer-Verlag</publisher-name><pub-id pub-id-type="doi">10.1016/j.ecolmodel.2003.11.004</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardozo</surname> <given-names>EF</given-names></name><name><surname>Andrade</surname> <given-names>A</given-names></name><name><surname>Mellors</surname> <given-names>JW</given-names></name><name><surname>Kuritzkes</surname> <given-names>DR</given-names></name><name><surname>Perelson</surname> <given-names>AS</given-names></name><name><surname>Ribeiro</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration</article-title><source>PLOS Pathogens</source><volume>13</volume><elocation-id>e1006478</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006478</pub-id><pub-id pub-id-type="pmid">28678879</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardozo</surname> <given-names>EF</given-names></name><name><surname>Apetrei</surname> <given-names>C</given-names></name><name><surname>Pandrea</surname> <given-names>I</given-names></name><name><surname>Ribeiro</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The dynamics of simian immunodeficiency virus after depletion of CD8+ cells</article-title><source>Immunological Reviews</source><volume>285</volume><fpage>26</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1111/imr.12691</pub-id><pub-id pub-id-type="pmid">30129200</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname> <given-names>TW</given-names></name><name><surname>Finzi</surname> <given-names>D</given-names></name><name><surname>Margolick</surname> <given-names>J</given-names></name><name><surname>Chadwick</surname> <given-names>K</given-names></name><name><surname>Schwartz</surname> <given-names>D</given-names></name><name><surname>Siliciano</surname> <given-names>RF</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency</article-title><source>Nature Medicine</source><volume>1</volume><fpage>1284</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1038/nm1295-1284</pub-id><pub-id pub-id-type="pmid">7489410</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname> <given-names>TW</given-names></name><name><surname>Carruth</surname> <given-names>L</given-names></name><name><surname>Finzi</surname> <given-names>D</given-names></name><name><surname>Shen</surname> <given-names>X</given-names></name><name><surname>DiGiuseppe</surname> <given-names>JA</given-names></name><name><surname>Taylor</surname> <given-names>H</given-names></name><name><surname>Hermankova</surname> <given-names>M</given-names></name><name><surname>Chadwick</surname> <given-names>K</given-names></name><name><surname>Margolick</surname> <given-names>J</given-names></name><name><surname>Quinn</surname> <given-names>TC</given-names></name><name><surname>Kuo</surname> <given-names>YH</given-names></name><name><surname>Brookmeyer</surname> <given-names>R</given-names></name><name><surname>Zeiger</surname> <given-names>MA</given-names></name><name><surname>Barditch-Crovo</surname> <given-names>P</given-names></name><name><surname>Siliciano</surname> <given-names>RF</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection</article-title><source>Nature</source><volume>387</volume><fpage>183</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1038/387183a0</pub-id><pub-id pub-id-type="pmid">9144289</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chute</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Stem cell homing</article-title><source>Current Opinion in Hematology</source><volume>13</volume><fpage>399</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1097/01.moh.0000245698.62511.3d</pub-id><pub-id pub-id-type="pmid">17053451</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conway</surname> <given-names>JM</given-names></name><name><surname>Perelson</surname> <given-names>AS</given-names></name><name><surname>Li</surname> <given-names>JZ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers</article-title><source>PLOS Computational Biology</source><volume>15</volume><elocation-id>e1007229</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1007229</pub-id><pub-id pub-id-type="pmid">31339888</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czechowicz</surname> <given-names>A</given-names></name><name><surname>Palchaudhuri</surname> <given-names>R</given-names></name><name><surname>Scheck</surname> <given-names>A</given-names></name><name><surname>Hu</surname> <given-names>Y</given-names></name><name><surname>Hoggatt</surname> <given-names>J</given-names></name><name><surname>Saez</surname> <given-names>B</given-names></name><name><surname>Pang</surname> <given-names>WW</given-names></name><name><surname>Mansour</surname> <given-names>MK</given-names></name><name><surname>Tate</surname> <given-names>TA</given-names></name><name><surname>Chan</surname> <given-names>YY</given-names></name><name><surname>Walck</surname> <given-names>E</given-names></name><name><surname>Wernig</surname> <given-names>G</given-names></name><name><surname>Shizuru</surname> <given-names>JA</given-names></name><name><surname>Winau</surname> <given-names>F</given-names></name><name><surname>Scadden</surname> <given-names>DT</given-names></name><name><surname>Rossi</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>617</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-08201-x</pub-id><pub-id pub-id-type="pmid">30728354</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Boer</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Understanding the failure of CD8+ T-cell vaccination against simian/human immunodeficiency virus</article-title><source>Journal of Virology</source><volume>81</volume><fpage>2838</fpage><lpage>2848</lpage><pub-id pub-id-type="doi">10.1128/JVI.01914-06</pub-id><pub-id pub-id-type="pmid">17202215</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doitsh</surname> <given-names>G</given-names></name><name><surname>Cavrois</surname> <given-names>M</given-names></name><name><surname>Lassen</surname> <given-names>KG</given-names></name><name><surname>Zepeda</surname> <given-names>O</given-names></name><name><surname>Yang</surname> <given-names>Z</given-names></name><name><surname>Santiago</surname> <given-names>ML</given-names></name><name><surname>Hebbeler</surname> <given-names>AM</given-names></name><name><surname>Greene</surname> <given-names>WC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue</article-title><source>Cell</source><volume>143</volume><fpage>789</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.11.001</pub-id><pub-id pub-id-type="pmid">21111238</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donahue</surname> <given-names>RE</given-names></name><name><surname>Srinivasula</surname> <given-names>S</given-names></name><name><surname>Uchida</surname> <given-names>N</given-names></name><name><surname>Kim</surname> <given-names>I</given-names></name><name><surname>St. Claire</surname> <given-names>A</given-names></name><name><surname>Duralde</surname> <given-names>G</given-names></name><name><surname>DeGrange</surname> <given-names>P</given-names></name><name><surname>St. Claire</surname> <given-names>M</given-names></name><name><surname>Reba</surname> <given-names>RC</given-names></name><name><surname>Bonifacino</surname> <given-names>AC</given-names></name><name><surname>Krouse</surname> <given-names>AE</given-names></name><name><surname>Metzger</surname> <given-names>ME</given-names></name><name><surname>Paik</surname> <given-names>CH</given-names></name><name><surname>Lane</surname> <given-names>HC</given-names></name><name><surname>Tisdale</surname> <given-names>JF</given-names></name><name><surname>Di Mascio</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Discordance in lymphoid tissue recovery following stem cell transplantation in rhesus macaques: an in vivo imaging study</article-title><source>Blood</source><volume>126</volume><fpage>2632</fpage><lpage>2641</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-07-657346</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douek</surname> <given-names>DC</given-names></name><name><surname>McFarland</surname> <given-names>RD</given-names></name><name><surname>Keiser</surname> <given-names>PH</given-names></name><name><surname>Gage</surname> <given-names>EA</given-names></name><name><surname>Massey</surname> <given-names>JM</given-names></name><name><surname>Haynes</surname> <given-names>BF</given-names></name><name><surname>Polis</surname> <given-names>MA</given-names></name><name><surname>Haase</surname> <given-names>AT</given-names></name><name><surname>Feinberg</surname> <given-names>MB</given-names></name><name><surname>Sullivan</surname> <given-names>JL</given-names></name><name><surname>Jamieson</surname> <given-names>BD</given-names></name><name><surname>Zack</surname> <given-names>JA</given-names></name><name><surname>Picker</surname> <given-names>LJ</given-names></name><name><surname>Koup</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Changes in thymic function with age and during the treatment of HIV infection</article-title><source>Nature</source><volume>396</volume><fpage>690</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1038/25374</pub-id><pub-id pub-id-type="pmid">9872319</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douek</surname> <given-names>DC</given-names></name><name><surname>Vescio</surname> <given-names>RA</given-names></name><name><surname>Betts</surname> <given-names>MR</given-names></name><name><surname>Brenchley</surname> <given-names>JM</given-names></name><name><surname>Hill</surname> <given-names>BJ</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Berenson</surname> <given-names>JR</given-names></name><name><surname>Collins</surname> <given-names>RH</given-names></name><name><surname>Koup</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Assessment of thymic output in adults after haematopoietic stemcell transplantation and prediction of T-cell reconstitution</article-title><source>The Lancet</source><volume>355</volume><fpage>1875</fpage><lpage>1881</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)02293-5</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douek</surname> <given-names>DC</given-names></name><name><surname>Picker</surname> <given-names>LJ</given-names></name><name><surname>Koup</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>T cell dynamics in HIV-1 infection</article-title><source>Annual Review of Immunology</source><volume>21</volume><fpage>265</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.21.120601.141053</pub-id><pub-id pub-id-type="pmid">12524385</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elemans</surname> <given-names>M</given-names></name><name><surname>Seich Al Basatena</surname> <given-names>NK</given-names></name><name><surname>Klatt</surname> <given-names>NR</given-names></name><name><surname>Gkekas</surname> <given-names>C</given-names></name><name><surname>Silvestri</surname> <given-names>G</given-names></name><name><surname>Asquith</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Why don't CD8+ T cells reduce the lifespan of SIV-infected cells in vivo?</article-title><source>PLOS Computational Biology</source><volume>7</volume><elocation-id>e1002200</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1002200</pub-id><pub-id pub-id-type="pmid">21990968</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farber</surname> <given-names>DL</given-names></name><name><surname>Yudanin</surname> <given-names>NA</given-names></name><name><surname>Restifo</surname> <given-names>NP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Human memory T cells: generation, compartmentalization and homeostasis</article-title><source>Nature Reviews Immunology</source><volume>14</volume><fpage>24</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1038/nri3567</pub-id><pub-id pub-id-type="pmid">24336101</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finzi</surname> <given-names>D</given-names></name><name><surname>Hermankova</surname> <given-names>M</given-names></name><name><surname>Pierson</surname> <given-names>T</given-names></name><name><surname>Carruth</surname> <given-names>LM</given-names></name><name><surname>Buck</surname> <given-names>C</given-names></name><name><surname>Chaisson</surname> <given-names>RE</given-names></name><name><surname>Quinn</surname> <given-names>TC</given-names></name><name><surname>Chadwick</surname> <given-names>K</given-names></name><name><surname>Margolick</surname> <given-names>J</given-names></name><name><surname>Brookmeyer</surname> <given-names>R</given-names></name><name><surname>Gallant</surname> <given-names>J</given-names></name><name><surname>Markowitz</surname> <given-names>M</given-names></name><name><surname>Ho</surname> <given-names>DD</given-names></name><name><surname>Richman</surname> <given-names>DD</given-names></name><name><surname>Siliciano</surname> <given-names>RF</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy</article-title><source>Science</source><volume>278</volume><fpage>1295</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.1126/science.278.5341.1295</pub-id><pub-id pub-id-type="pmid">9360927</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldrath</surname> <given-names>AW</given-names></name><name><surname>Luckey</surname> <given-names>CJ</given-names></name><name><surname>Park</surname> <given-names>R</given-names></name><name><surname>Benoist</surname> <given-names>C</given-names></name><name><surname>Mathis</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The molecular program induced in T cells undergoing homeostatic proliferation</article-title><source>PNAS</source><volume>101</volume><fpage>16885</fpage><lpage>16890</lpage><pub-id pub-id-type="doi">10.1073/pnas.0407417101</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillaume</surname> <given-names>T</given-names></name><name><surname>Rubinstein</surname> <given-names>DB</given-names></name><name><surname>Symann</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation</article-title><source>Blood</source><volume>92</volume><fpage>1471</fpage><lpage>1490</lpage><pub-id pub-id-type="doi">10.1182/blood.V92.5.1471</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname> <given-names>RK</given-names></name><name><surname>Abdul-Jawad</surname> <given-names>S</given-names></name><name><surname>McCoy</surname> <given-names>LE</given-names></name><name><surname>Mok</surname> <given-names>HP</given-names></name><name><surname>Peppa</surname> <given-names>D</given-names></name><name><surname>Salgado</surname> <given-names>M</given-names></name><name><surname>Martinez-Picado</surname> <given-names>J</given-names></name><name><surname>Nijhuis</surname> <given-names>M</given-names></name><name><surname>Wensing</surname> <given-names>AMJ</given-names></name><name><surname>Lee</surname> <given-names>H</given-names></name><name><surname>Grant</surname> <given-names>P</given-names></name><name><surname>Nastouli</surname> <given-names>E</given-names></name><name><surname>Lambert</surname> <given-names>J</given-names></name><name><surname>Pace</surname> <given-names>M</given-names></name><name><surname>Salasc</surname> <given-names>F</given-names></name><name><surname>Monit</surname> <given-names>C</given-names></name><name><surname>Innes</surname> <given-names>AJ</given-names></name><name><surname>Muir</surname> <given-names>L</given-names></name><name><surname>Waters</surname> <given-names>L</given-names></name><name><surname>Frater</surname> <given-names>J</given-names></name><name><surname>Lever</surname> <given-names>AML</given-names></name><name><surname>Edwards</surname> <given-names>SG</given-names></name><name><surname>Gabriel</surname> <given-names>IH</given-names></name><name><surname>Olavarria</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation</article-title><source>Nature</source><volume>568</volume><fpage>244</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1027-4</pub-id><pub-id pub-id-type="pmid">30836379</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname> <given-names>RK</given-names></name><name><surname>Peppa</surname> <given-names>D</given-names></name><name><surname>Hill</surname> <given-names>AL</given-names></name><name><surname>Gálvez</surname> <given-names>C</given-names></name><name><surname>Salgado</surname> <given-names>M</given-names></name><name><surname>Pace</surname> <given-names>M</given-names></name><name><surname>McCoy</surname> <given-names>LE</given-names></name><name><surname>Griffith</surname> <given-names>SA</given-names></name><name><surname>Thornhill</surname> <given-names>J</given-names></name><name><surname>Alrubayyi</surname> <given-names>A</given-names></name><name><surname>Huyveneers</surname> <given-names>LEP</given-names></name><name><surname>Nastouli</surname> <given-names>E</given-names></name><name><surname>Grant</surname> <given-names>P</given-names></name><name><surname>Edwards</surname> <given-names>SG</given-names></name><name><surname>Innes</surname> <given-names>AJ</given-names></name><name><surname>Frater</surname> <given-names>J</given-names></name><name><surname>Nijhuis</surname> <given-names>M</given-names></name><name><surname>Wensing</surname> <given-names>AMJ</given-names></name><name><surname>Martinez-Picado</surname> <given-names>J</given-names></name><name><surname>Olavarria</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report</article-title><source>The Lancet HIV</source><volume>7</volume><fpage>e340</fpage><lpage>e347</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(20)30069-2</pub-id><pub-id pub-id-type="pmid">32169158</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haworth</surname> <given-names>KG</given-names></name><name><surname>Peterson</surname> <given-names>CW</given-names></name><name><surname>Kiem</surname> <given-names>HP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CCR5-edited gene therapies for HIV cure: closing the door to viral entry</article-title><source>Cytotherapy</source><volume>19</volume><fpage>1325</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1016/j.jcyt.2017.05.013</pub-id><pub-id pub-id-type="pmid">28751153</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henrich</surname> <given-names>TJ</given-names></name><name><surname>Hu</surname> <given-names>Z</given-names></name><name><surname>Li</surname> <given-names>JZ</given-names></name><name><surname>Sciaranghella</surname> <given-names>G</given-names></name><name><surname>Busch</surname> <given-names>MP</given-names></name><name><surname>Keating</surname> <given-names>SM</given-names></name><name><surname>Gallien</surname> <given-names>S</given-names></name><name><surname>Lin</surname> <given-names>NH</given-names></name><name><surname>Giguel</surname> <given-names>FF</given-names></name><name><surname>Lavoie</surname> <given-names>L</given-names></name><name><surname>Ho</surname> <given-names>VT</given-names></name><name><surname>Armand</surname> <given-names>P</given-names></name><name><surname>Soiffer</surname> <given-names>RJ</given-names></name><name><surname>Sagar</surname> <given-names>M</given-names></name><name><surname>Lacasce</surname> <given-names>AS</given-names></name><name><surname>Kuritzkes</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation</article-title><source>Journal of Infectious Diseases</source><volume>207</volume><fpage>1694</fpage><lpage>1702</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit086</pub-id><pub-id pub-id-type="pmid">23460751</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henrich</surname> <given-names>TJ</given-names></name><name><surname>Hanhauser</surname> <given-names>E</given-names></name><name><surname>Marty</surname> <given-names>FM</given-names></name><name><surname>Sirignano</surname> <given-names>MN</given-names></name><name><surname>Keating</surname> <given-names>S</given-names></name><name><surname>Lee</surname> <given-names>TH</given-names></name><name><surname>Robles</surname> <given-names>YP</given-names></name><name><surname>Davis</surname> <given-names>BT</given-names></name><name><surname>Li</surname> <given-names>JZ</given-names></name><name><surname>Heisey</surname> <given-names>A</given-names></name><name><surname>Hill</surname> <given-names>AL</given-names></name><name><surname>Busch</surname> <given-names>MP</given-names></name><name><surname>Armand</surname> <given-names>P</given-names></name><name><surname>Soiffer</surname> <given-names>RJ</given-names></name><name><surname>Altfeld</surname> <given-names>M</given-names></name><name><surname>Kuritzkes</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases</article-title><source>Annals of Internal Medicine</source><volume>161</volume><elocation-id>319</elocation-id><pub-id pub-id-type="doi">10.7326/M14-1027</pub-id><pub-id pub-id-type="pmid">25047577</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henrich</surname> <given-names>TJ</given-names></name><name><surname>Hanhauser</surname> <given-names>E</given-names></name><name><surname>Harrison</surname> <given-names>LJ</given-names></name><name><surname>Palmer</surname> <given-names>CD</given-names></name><name><surname>Romero-Tejeda</surname> <given-names>M</given-names></name><name><surname>Jost</surname> <given-names>S</given-names></name><name><surname>Bosch</surname> <given-names>RJ</given-names></name><name><surname>Kuritzkes</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CCR5-Δ32 heterozygosity, HIV-1 reservoir size, and lymphocyte activation in individuals receiving Long-term suppressive antiretroviral therapy</article-title><source>Journal of Infectious Diseases</source><volume>213</volume><fpage>766</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiv504</pub-id><pub-id pub-id-type="pmid">26512140</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname> <given-names>AL</given-names></name><name><surname>Rosenbloom</surname> <given-names>DI</given-names></name><name><surname>Fu</surname> <given-names>F</given-names></name><name><surname>Nowak</surname> <given-names>MA</given-names></name><name><surname>Siliciano</surname> <given-names>RF</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1</article-title><source>PNAS</source><volume>111</volume><fpage>13475</fpage><lpage>13480</lpage><pub-id pub-id-type="doi">10.1073/pnas.1406663111</pub-id><pub-id pub-id-type="pmid">25097264</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname> <given-names>AL</given-names></name><name><surname>Rosenbloom</surname> <given-names>DIS</given-names></name><name><surname>Nowak</surname> <given-names>MA</given-names></name><name><surname>Siliciano</surname> <given-names>RF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Insight into treatment of HIV infection from viral dynamics models</article-title><source>Immunological Reviews</source><volume>285</volume><fpage>9</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1111/imr.12698</pub-id><pub-id pub-id-type="pmid">30129208</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname> <given-names>O</given-names></name><name><surname>Larsen</surname> <given-names>K</given-names></name><name><surname>Polacino</surname> <given-names>P</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Anderson</surname> <given-names>D</given-names></name><name><surname>Song</surname> <given-names>R</given-names></name><name><surname>Ruprecht</surname> <given-names>RM</given-names></name><name><surname>Hu</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Pathogenic infection of Macaca nemestrina with a CCR5-tropic subtype-C simian-human immunodeficiency virus</article-title><source>Retrovirology</source><volume>6</volume><elocation-id>65</elocation-id><pub-id pub-id-type="doi">10.1186/1742-4690-6-65</pub-id><pub-id pub-id-type="pmid">19602283</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hütter</surname> <given-names>G</given-names></name><name><surname>Nowak</surname> <given-names>D</given-names></name><name><surname>Mossner</surname> <given-names>M</given-names></name><name><surname>Ganepola</surname> <given-names>S</given-names></name><name><surname>Müssig</surname> <given-names>A</given-names></name><name><surname>Allers</surname> <given-names>K</given-names></name><name><surname>Schneider</surname> <given-names>T</given-names></name><name><surname>Hofmann</surname> <given-names>J</given-names></name><name><surname>Kücherer</surname> <given-names>C</given-names></name><name><surname>Blau</surname> <given-names>O</given-names></name><name><surname>Blau</surname> <given-names>IW</given-names></name><name><surname>Hofmann</surname> <given-names>WK</given-names></name><name><surname>Thiel</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Long-Term control of HIV by CCR5 Delta32/Delta32 Stem-Cell transplantation</article-title><source>New England Journal of Medicine</source><volume>360</volume><fpage>692</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0802905</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jameson</surname> <given-names>SC</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Maintaining the norm: t-cell homeostasis</article-title><source>Nature Reviews Immunology</source><volume>2</volume><fpage>547</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1038/nri853</pub-id><pub-id pub-id-type="pmid">12154374</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaech</surname> <given-names>SM</given-names></name><name><surname>Wherry</surname> <given-names>EJ</given-names></name><name><surname>Ahmed</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Effector and memory T-cell differentiation: implications for vaccine development</article-title><source>Nature Reviews Immunology</source><volume>2</volume><fpage>251</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1038/nri778</pub-id><pub-id pub-id-type="pmid">12001996</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kieper</surname> <given-names>WC</given-names></name><name><surname>Jameson</surname> <given-names>SC</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Homeostatic expansion and phenotypic conversion of naïve T cells in response to self peptide/MHC ligands</article-title><source>PNAS</source><volume>96</volume><fpage>13306</fpage><lpage>13311</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.23.13306</pub-id><pub-id pub-id-type="pmid">10557316</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klatt</surname> <given-names>NR</given-names></name><name><surname>Shudo</surname> <given-names>E</given-names></name><name><surname>Ortiz</surname> <given-names>AM</given-names></name><name><surname>Engram</surname> <given-names>JC</given-names></name><name><surname>Paiardini</surname> <given-names>M</given-names></name><name><surname>Lawson</surname> <given-names>B</given-names></name><name><surname>Miller</surname> <given-names>MD</given-names></name><name><surname>Else</surname> <given-names>J</given-names></name><name><surname>Pandrea</surname> <given-names>I</given-names></name><name><surname>Estes</surname> <given-names>JD</given-names></name><name><surname>Apetrei</surname> <given-names>C</given-names></name><name><surname>Schmitz</surname> <given-names>JE</given-names></name><name><surname>Ribeiro</surname> <given-names>RM</given-names></name><name><surname>Perelson</surname> <given-names>AS</given-names></name><name><surname>Silvestri</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells</article-title><source>PLOS Pathogens</source><volume>6</volume><elocation-id>e1000747</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000747</pub-id><pub-id pub-id-type="pmid">20126441</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krenger</surname> <given-names>W</given-names></name><name><surname>Blazar</surname> <given-names>BR</given-names></name><name><surname>Holländer</surname> <given-names>GA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Thymic T-cell development in Allogeneic stem cell transplantation</article-title><source>Blood</source><volume>117</volume><fpage>6768</fpage><lpage>6776</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-02-334623</pub-id><pub-id pub-id-type="pmid">21427289</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapidot</surname> <given-names>T</given-names></name><name><surname>Dar</surname> <given-names>A</given-names></name><name><surname>Kollet</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>How do stem cells find their way home?</article-title><source>Blood</source><volume>106</volume><fpage>1901</fpage><lpage>1910</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-04-1417</pub-id><pub-id pub-id-type="pmid">15890683</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lavielle</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><source>Mixed Effects Models for the Population Approach: Models, Tasks, Methods and Tools</source><publisher-loc>Boca Raton</publisher-loc><publisher-name>Chapman and Hall/CRC</publisher-name></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Saout</surname> <given-names>C</given-names></name><name><surname>Mennechet</surname> <given-names>S</given-names></name><name><surname>Taylor</surname> <given-names>N</given-names></name><name><surname>Hernandez</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Memory-like CD8+ and CD4+ T cells cooperate to break peripheral tolerance under lymphopenic conditions</article-title><source>PNAS</source><volume>105</volume><fpage>19414</fpage><lpage>19419</lpage><pub-id pub-id-type="doi">10.1073/pnas.0807743105</pub-id><pub-id pub-id-type="pmid">19033460</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Margolick</surname> <given-names>JB</given-names></name><name><surname>Donnenberg</surname> <given-names>AD</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>T-cell homeostasis in HIV-1 infection</article-title><source>Seminars in Immunology</source><volume>9</volume><fpage>381</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1006/smim.1997.0096</pub-id><pub-id pub-id-type="pmid">9405267</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markowitz</surname> <given-names>M</given-names></name><name><surname>Louie</surname> <given-names>M</given-names></name><name><surname>Hurley</surname> <given-names>A</given-names></name><name><surname>Sun</surname> <given-names>E</given-names></name><name><surname>Di Mascio</surname> <given-names>M</given-names></name><name><surname>Perelson</surname> <given-names>AS</given-names></name><name><surname>Ho</surname> <given-names>DD</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo</article-title><source>Journal of Virology</source><volume>77</volume><fpage>5037</fpage><lpage>5038</lpage><pub-id pub-id-type="doi">10.1128/JVI.77.8.5037-5038.2003</pub-id><pub-id pub-id-type="pmid">12663814</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matrajt</surname> <given-names>L</given-names></name><name><surname>Younan</surname> <given-names>PM</given-names></name><name><surname>Kiem</surname> <given-names>HP</given-names></name><name><surname>Schiffer</surname> <given-names>JT</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The majority of CD4+ T-cell depletion during acute simian-human immunodeficiency virus SHIV89.6P infection occurs in uninfected cells</article-title><source>Journal of Virology</source><volume>88</volume><fpage>3202</fpage><lpage>3212</lpage><pub-id pub-id-type="doi">10.1128/JVI.03428-13</pub-id><pub-id pub-id-type="pmid">24390339</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCune</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Thymic function in HIV-1 disease</article-title><source>Seminars in Immunology</source><volume>9</volume><fpage>397</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1006/smim.1997.0098</pub-id><pub-id pub-id-type="pmid">9405269</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehr</surname> <given-names>R</given-names></name><name><surname>Perelson</surname> <given-names>AS</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Blind T-cell homeostasis and the CD4/CD8 ratio in the Thymus and peripheral blood</article-title><source>Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology</source><volume>14</volume><fpage>387</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1097/00042560-199704150-00001</pub-id><pub-id pub-id-type="pmid">9170412</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okoye</surname> <given-names>A</given-names></name><name><surname>Meier-Schellersheim</surname> <given-names>M</given-names></name><name><surname>Brenchley</surname> <given-names>JM</given-names></name><name><surname>Hagen</surname> <given-names>SI</given-names></name><name><surname>Walker</surname> <given-names>JM</given-names></name><name><surname>Rohankhedkar</surname> <given-names>M</given-names></name><name><surname>Lum</surname> <given-names>R</given-names></name><name><surname>Edgar</surname> <given-names>JB</given-names></name><name><surname>Planer</surname> <given-names>SL</given-names></name><name><surname>Legasse</surname> <given-names>A</given-names></name><name><surname>Sylwester</surname> <given-names>AW</given-names></name><name><surname>Piatak</surname> <given-names>M</given-names></name><name><surname>Lifson</surname> <given-names>JD</given-names></name><name><surname>Maino</surname> <given-names>VC</given-names></name><name><surname>Sodora</surname> <given-names>DL</given-names></name><name><surname>Douek</surname> <given-names>DC</given-names></name><name><surname>Axthelm</surname> <given-names>MK</given-names></name><name><surname>Grossman</surname> <given-names>Z</given-names></name><name><surname>Picker</surname> <given-names>LJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Progressive CD4+ central–memory T cell decline results in CD4+ effector–memory insufficiency and overt disease in chronic SIV infection</article-title><source>Journal of Experimental Medicine</source><volume>204</volume><fpage>2171</fpage><lpage>2185</lpage><pub-id pub-id-type="doi">10.1084/jem.20070567</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okoye</surname> <given-names>AA</given-names></name><name><surname>Rohankhedkar</surname> <given-names>M</given-names></name><name><surname>Abana</surname> <given-names>C</given-names></name><name><surname>Pattenn</surname> <given-names>A</given-names></name><name><surname>Reyes</surname> <given-names>M</given-names></name><name><surname>Pexton</surname> <given-names>C</given-names></name><name><surname>Lum</surname> <given-names>R</given-names></name><name><surname>Sylwester</surname> <given-names>A</given-names></name><name><surname>Planer</surname> <given-names>SL</given-names></name><name><surname>Legasse</surname> <given-names>A</given-names></name><name><surname>Park</surname> <given-names>BS</given-names></name><name><surname>Piatak</surname> <given-names>M</given-names></name><name><surname>Lifson</surname> <given-names>JD</given-names></name><name><surname>Axthelm</surname> <given-names>MK</given-names></name><name><surname>Picker</surname> <given-names>LJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Naive T cells are dispensable for memory CD4+ T cell homeostasis in progressive simian immunodeficiency virus infection</article-title><source>Journal of Experimental Medicine</source><volume>209</volume><fpage>641</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1084/jem.20112071</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okoye</surname> <given-names>AA</given-names></name><name><surname>Picker</surname> <given-names>LJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>P. L. J., CD4+ t‐cell depletion in HIV infection: mechanisms of immunological failure</article-title><source>Immunological Reviews</source><volume>254</volume><fpage>54</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1111/imr.12066</pub-id><pub-id pub-id-type="pmid">23772614</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palchaudhuri</surname> <given-names>R</given-names></name><name><surname>Saez</surname> <given-names>B</given-names></name><name><surname>Hoggatt</surname> <given-names>J</given-names></name><name><surname>Schajnovitz</surname> <given-names>A</given-names></name><name><surname>Sykes</surname> <given-names>DB</given-names></name><name><surname>Tate</surname> <given-names>TA</given-names></name><name><surname>Czechowicz</surname> <given-names>A</given-names></name><name><surname>Kfoury</surname> <given-names>Y</given-names></name><name><surname>Ruchika</surname> <given-names>F</given-names></name><name><surname>Rossi</surname> <given-names>DJ</given-names></name><name><surname>Verdine</surname> <given-names>GL</given-names></name><name><surname>Mansour</surname> <given-names>MK</given-names></name><name><surname>Scadden</surname> <given-names>DT</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin</article-title><source>Nature Biotechnology</source><volume>34</volume><fpage>738</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1038/nbt.3584</pub-id><pub-id pub-id-type="pmid">27272386</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandit</surname> <given-names>A</given-names></name><name><surname>de Boer</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>HIV-1 CCR5 gene therapy will fail unless it is combined with a suicide gene</article-title><source>Scientific Reports</source><volume>5</volume><elocation-id>srep18088</elocation-id><pub-id pub-id-type="doi">10.1038/srep18088</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perelson</surname> <given-names>AS</given-names></name><name><surname>Essunger</surname> <given-names>P</given-names></name><name><surname>Cao</surname> <given-names>Y</given-names></name><name><surname>Vesanen</surname> <given-names>M</given-names></name><name><surname>Hurley</surname> <given-names>A</given-names></name><name><surname>Saksela</surname> <given-names>K</given-names></name><name><surname>Markowitz</surname> <given-names>M</given-names></name><name><surname>Ho</surname> <given-names>DD</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Decay characteristics of HIV-1-infected compartments during combination therapy</article-title><source>Nature</source><volume>387</volume><fpage>188</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1038/387188a0</pub-id><pub-id pub-id-type="pmid">9144290</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perelson</surname> <given-names>AS</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Modelling viral and immune system dynamics</article-title><source>Nature Reviews Immunology</source><volume>2</volume><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1038/nri700</pub-id><pub-id pub-id-type="pmid">11905835</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname> <given-names>CW</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Norman</surname> <given-names>KK</given-names></name><name><surname>Norgaard</surname> <given-names>ZK</given-names></name><name><surname>Humbert</surname> <given-names>O</given-names></name><name><surname>Tse</surname> <given-names>CK</given-names></name><name><surname>Yan</surname> <given-names>JJ</given-names></name><name><surname>Trimble</surname> <given-names>RG</given-names></name><name><surname>Shivak</surname> <given-names>DA</given-names></name><name><surname>Rebar</surname> <given-names>EJ</given-names></name><name><surname>Gregory</surname> <given-names>PD</given-names></name><name><surname>Holmes</surname> <given-names>MC</given-names></name><name><surname>Kiem</surname> <given-names>HP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates</article-title><source>Blood</source><volume>127</volume><fpage>2416</fpage><lpage>2426</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-09-672337</pub-id><pub-id pub-id-type="pmid">26980728</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname> <given-names>CW</given-names></name><name><surname>Benne</surname> <given-names>C</given-names></name><name><surname>Polacino</surname> <given-names>P</given-names></name><name><surname>Kaur</surname> <given-names>J</given-names></name><name><surname>McAllister</surname> <given-names>CE</given-names></name><name><surname>Filali-Mouhim</surname> <given-names>A</given-names></name><name><surname>Obenza</surname> <given-names>W</given-names></name><name><surname>Pecor</surname> <given-names>TA</given-names></name><name><surname>Huang</surname> <given-names>ML</given-names></name><name><surname>Baldessari</surname> <given-names>A</given-names></name><name><surname>Murnane</surname> <given-names>RD</given-names></name><name><surname>Woolfrey</surname> <given-names>AE</given-names></name><name><surname>Jerome</surname> <given-names>KR</given-names></name><name><surname>Hu</surname> <given-names>SL</given-names></name><name><surname>Klatt</surname> <given-names>NR</given-names></name><name><surname>DeRosa</surname> <given-names>S</given-names></name><name><surname>Sékaly</surname> <given-names>RP</given-names></name><name><surname>Kiem</surname> <given-names>HP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Loss of immune homeostasis dictates SHIV rebound after stem-cell transplantation</article-title><source>JCI Insight</source><volume>2</volume><elocation-id>e91230</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.91230</pub-id><pub-id pub-id-type="pmid">28239658</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname> <given-names>CW</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Deleage</surname> <given-names>C</given-names></name><name><surname>Reddy</surname> <given-names>S</given-names></name><name><surname>Kaur</surname> <given-names>J</given-names></name><name><surname>Polacino</surname> <given-names>P</given-names></name><name><surname>Reik</surname> <given-names>A</given-names></name><name><surname>Huang</surname> <given-names>ML</given-names></name><name><surname>Jerome</surname> <given-names>KR</given-names></name><name><surname>Hu</surname> <given-names>SL</given-names></name><name><surname>Holmes</surname> <given-names>MC</given-names></name><name><surname>Estes</surname> <given-names>JD</given-names></name><name><surname>Kiem</surname> <given-names>HP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Differential impact of transplantation on peripheral and tissue-associated viral reservoirs: implications for HIV gene therapy</article-title><source>PLOS Pathogens</source><volume>14</volume><elocation-id>e1006956</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006956</pub-id><pub-id pub-id-type="pmid">29672640</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname> <given-names>CW</given-names></name><name><surname>Kiem</surname> <given-names>HP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Lessons from London and Berlin: designing A scalable gene therapy approach for HIV cure</article-title><source>Cell Stem Cell</source><volume>24</volume><fpage>685</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2019.04.010</pub-id><pub-id pub-id-type="pmid">31051132</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Prague</surname> <given-names>M</given-names></name><name><surname>Gerold</surname> <given-names>JM</given-names></name><name><surname>Balelli</surname> <given-names>I</given-names></name><name><surname>Pasin</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>JZ</given-names></name><name><surname>Barouch</surname> <given-names>DH</given-names></name><name><surname>Whitney</surname> <given-names>JB</given-names></name><name><surname>Hill</surname> <given-names>AL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Viral rebound kinetics following single and combination immunotherapy for HIV/SIV</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/700401</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radtke</surname> <given-names>S</given-names></name><name><surname>Adair</surname> <given-names>JE</given-names></name><name><surname>Giese</surname> <given-names>MA</given-names></name><name><surname>Chan</surname> <given-names>YY</given-names></name><name><surname>Norgaard</surname> <given-names>ZK</given-names></name><name><surname>Enstrom</surname> <given-names>M</given-names></name><name><surname>Haworth</surname> <given-names>KG</given-names></name><name><surname>Schefter</surname> <given-names>LE</given-names></name><name><surname>Kiem</surname> <given-names>HP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A distinct hematopoietic stem cell population for rapid multilineage engraftment in nonhuman primates</article-title><source>Science Translational Medicine</source><volume>9</volume><elocation-id>eaan1145</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aan1145</pub-id><pub-id pub-id-type="pmid">29093179</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramratnam</surname> <given-names>B</given-names></name><name><surname>Bonhoeffer</surname> <given-names>S</given-names></name><name><surname>Binley</surname> <given-names>J</given-names></name><name><surname>Hurley</surname> <given-names>A</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Mittler</surname> <given-names>JE</given-names></name><name><surname>Markowitz</surname> <given-names>M</given-names></name><name><surname>Moore</surname> <given-names>JP</given-names></name><name><surname>Perelson</surname> <given-names>AS</given-names></name><name><surname>Ho</surname> <given-names>DD</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis</article-title><source>The Lancet</source><volume>354</volume><fpage>1782</fpage><lpage>1785</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(99)02035-8</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reeves</surname> <given-names>DB</given-names></name><name><surname>Peterson</surname> <given-names>CW</given-names></name><name><surname>Kiem</surname> <given-names>H-P</given-names></name><name><surname>Schiffer</surname> <given-names>JT</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Autologous stem cell transplantation disrupts adaptive immune responses during rebound simian/Human immunodeficiency virus viremia</article-title><source>Journal of Virology</source><volume>91</volume><elocation-id>e00095-00017</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.00095-17</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roux</surname> <given-names>E</given-names></name><name><surname>Dumont-Girard</surname> <given-names>F</given-names></name><name><surname>Starobinski</surname> <given-names>M</given-names></name><name><surname>Siegrist</surname> <given-names>CA</given-names></name><name><surname>Helg</surname> <given-names>C</given-names></name><name><surname>Chapuis</surname> <given-names>B</given-names></name><name><surname>Roosnek</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity</article-title><source>Blood</source><volume>96</volume><fpage>2299</fpage><lpage>2303</lpage><pub-id pub-id-type="doi">10.1182/blood.V96.6.2299</pub-id><pub-id pub-id-type="pmid">10979980</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salgado</surname> <given-names>M</given-names></name><name><surname>Kwon</surname> <given-names>M</given-names></name><name><surname>Gálvez</surname> <given-names>C</given-names></name><name><surname>Badiola</surname> <given-names>J</given-names></name><name><surname>Nijhuis</surname> <given-names>M</given-names></name><name><surname>Bandera</surname> <given-names>A</given-names></name><name><surname>Balsalobre</surname> <given-names>P</given-names></name><name><surname>Miralles</surname> <given-names>P</given-names></name><name><surname>Buño</surname> <given-names>I</given-names></name><name><surname>Martinez-Laperche</surname> <given-names>C</given-names></name><name><surname>Vilaplana</surname> <given-names>C</given-names></name><name><surname>Jurado</surname> <given-names>M</given-names></name><name><surname>Clotet</surname> <given-names>B</given-names></name><name><surname>Wensing</surname> <given-names>A</given-names></name><name><surname>Martinez-Picado</surname> <given-names>J</given-names></name><name><surname>Diez-Martin</surname> <given-names>JL</given-names></name><collab>IciStem Consortium</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Mechanisms that contribute to a profound reduction of the HIV-1 reservoir after allogeneic stem cell transplant</article-title><source>Annals of Internal Medicine</source><volume>169</volume><fpage>674</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.7326/M18-0759</pub-id><pub-id pub-id-type="pmid">30326031</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallusto</surname> <given-names>F</given-names></name><name><surname>Geginat</surname> <given-names>J</given-names></name><name><surname>Lanzavecchia</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Central memory and effector memory T cell subsets: function, generation, and maintenance</article-title><source>Annual Review of Immunology</source><volume>22</volume><fpage>745</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.22.012703.104702</pub-id><pub-id pub-id-type="pmid">15032595</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schluns</surname> <given-names>KS</given-names></name><name><surname>Kieper</surname> <given-names>WC</given-names></name><name><surname>Jameson</surname> <given-names>SC</given-names></name><name><surname>Lefrançois</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells <italic>in vivo</italic></article-title><source>Nature Immunology</source><volume>1</volume><fpage>426</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1038/80868</pub-id><pub-id pub-id-type="pmid">11062503</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schluns</surname> <given-names>KS</given-names></name><name><surname>Williams</surname> <given-names>K</given-names></name><name><surname>Ma</surname> <given-names>A</given-names></name><name><surname>Zheng</surname> <given-names>XX</given-names></name><name><surname>Lefrançois</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells</article-title><source>The Journal of Immunology</source><volume>168</volume><fpage>4827</fpage><lpage>4831</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.168.10.4827</pub-id><pub-id pub-id-type="pmid">11994430</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shridhar</surname> <given-names>V</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Gupta</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The CD8 antiviral factor (CAF) can suppress HIV-1 transcription from the long terminal repeat (LTR) promoter in the absence of elements upstream of the CATATAA box</article-title><source>Virology Journal</source><volume>11</volume><elocation-id>130</elocation-id><pub-id pub-id-type="doi">10.1186/1743-422X-11-130</pub-id><pub-id pub-id-type="pmid">25048949</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spits</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Development of alphabeta T cells in the human Thymus</article-title><source>Nature Reviews Immunology</source><volume>2</volume><fpage>760</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1038/nri913</pub-id><pub-id pub-id-type="pmid">12360214</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sprent</surname> <given-names>J</given-names></name><name><surname>Surh</surname> <given-names>CD</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells</article-title><source>Nature Immunology</source><volume>12</volume><fpage>478</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1038/ni.2018</pub-id><pub-id pub-id-type="pmid">21739670</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srikanthan</surname> <given-names>MA</given-names></name><name><surname>Humbert</surname> <given-names>O</given-names></name><name><surname>Haworth</surname> <given-names>KG</given-names></name><name><surname>Ironside</surname> <given-names>C</given-names></name><name><surname>Rajawat</surname> <given-names>YS</given-names></name><name><surname>Blazar</surname> <given-names>BR</given-names></name><name><surname>Palchaudhuri</surname> <given-names>R</given-names></name><name><surname>Boitano</surname> <given-names>AE</given-names></name><name><surname>Cooke</surname> <given-names>MP</given-names></name><name><surname>Scadden</surname> <given-names>DT</given-names></name><name><surname>Kiem</surname> <given-names>HP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Effective Multi-lineage engraftment in a mouse model of fanconi Anemia using Non-genotoxic Antibody-Based conditioning</article-title><source>Molecular Therapy - Methods &amp; Clinical Development</source><volume>17</volume><fpage>455</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2020.02.001</pub-id><pub-id pub-id-type="pmid">32226796</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiehl</surname> <given-names>T</given-names></name><name><surname>Baran</surname> <given-names>N</given-names></name><name><surname>Ho</surname> <given-names>AD</given-names></name><name><surname>Marciniak-Czochra</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Clonal selection and therapy resistance in acute leukaemias: mathematical modelling explains different proliferation patterns at diagnosis and relapse</article-title><source>Journal of the Royal Society Interface</source><volume>11</volume><elocation-id>20140079</elocation-id><pub-id pub-id-type="doi">10.1098/rsif.2014.0079</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiehl</surname> <given-names>T</given-names></name><name><surname>Marciniak-Czochra</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Characterization of stem cells using mathematical models of multistage cell lineages</article-title><source>Mathematical and Computer Modelling</source><volume>53</volume><fpage>1505</fpage><lpage>1517</lpage><pub-id pub-id-type="doi">10.1016/j.mcm.2010.03.057</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiehl</surname> <given-names>T</given-names></name><name><surname>Marciniak-Czochra</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Stem cell self-renewal in regeneration and Cancer: insights from mathematical modeling</article-title><source>Current Opinion in Systems Biology</source><volume>5</volume><fpage>112</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.coisb.2017.09.006</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname> <given-names>JT</given-names></name><name><surname>Dudl</surname> <given-names>E</given-names></name><name><surname>LeRoy</surname> <given-names>E</given-names></name><name><surname>Murray</surname> <given-names>R</given-names></name><name><surname>Sprent</surname> <given-names>J</given-names></name><name><surname>Weinberg</surname> <given-names>KI</given-names></name><name><surname>Surh</surname> <given-names>CD</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>IL-7 is critical for homeostatic proliferation and survival of naive T cells</article-title><source>PNAS</source><volume>98</volume><fpage>8732</fpage><lpage>8737</lpage><pub-id pub-id-type="doi">10.1073/pnas.161126098</pub-id><pub-id pub-id-type="pmid">11447288</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanchot</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Differential requirements for survival and proliferation of CD8 na&amp;iuml;ve or memory T cells</article-title><source>Science</source><volume>276</volume><fpage>2057</fpage><lpage>2062</lpage><pub-id pub-id-type="doi">10.1126/science.276.5321.2057</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tebas</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV</article-title><source>New England Journal of Medicine</source><volume>370</volume><fpage>901</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1300662</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voehringer</surname> <given-names>D</given-names></name><name><surname>Liang</surname> <given-names>HE</given-names></name><name><surname>Locksley</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Homeostasis and effector function of lymphopenia-induced &quot;memory-like&quot; T cells in constitutively T cell-depleted mice</article-title><source>The Journal of Immunology</source><volume>180</volume><fpage>4742</fpage><lpage>4753</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.180.7.4742</pub-id><pub-id pub-id-type="pmid">18354198</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wodarz</surname> <given-names>D</given-names></name><name><surname>Page</surname> <given-names>KM</given-names></name><name><surname>Arnaout</surname> <given-names>RA</given-names></name><name><surname>Thomsen</surname> <given-names>AR</given-names></name><name><surname>Lifson</surname> <given-names>JD</given-names></name><name><surname>Nowak</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A new theory of cytotoxic T–lymphocyte memory: implications for HIV treatment</article-title><source>Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences</source><volume>355</volume><fpage>329</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1098/rstb.2000.0570</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wodarz</surname> <given-names>D</given-names></name><name><surname>Nowak</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Specific therapy regimes could lead to long-term immunological control of HIV</article-title><source>PNAS</source><volume>96</volume><fpage>14464</fpage><lpage>14469</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.25.14464</pub-id><pub-id pub-id-type="pmid">10588728</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname> <given-names>JK</given-names></name><name><surname>Strain</surname> <given-names>MC</given-names></name><name><surname>Porrata</surname> <given-names>R</given-names></name><name><surname>Reay</surname> <given-names>E</given-names></name><name><surname>Sankaran-Walters</surname> <given-names>S</given-names></name><name><surname>Ignacio</surname> <given-names>CC</given-names></name><name><surname>Russell</surname> <given-names>T</given-names></name><name><surname>Pillai</surname> <given-names>SK</given-names></name><name><surname>Looney</surname> <given-names>DJ</given-names></name><name><surname>Dandekar</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>In vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells</article-title><source>PLOS Pathogens</source><volume>6</volume><elocation-id>e1000748</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000748</pub-id><pub-id pub-id-type="pmid">20126442</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaitseva</surname> <given-names>MB</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Rabin</surname> <given-names>RL</given-names></name><name><surname>Tiffany</surname> <given-names>HL</given-names></name><name><surname>Farber</surname> <given-names>JM</given-names></name><name><surname>Peden</surname> <given-names>KW</given-names></name><name><surname>Murphy</surname> <given-names>PM</given-names></name><name><surname>Golding</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection</article-title><source>Journal of Immunology</source><volume>161</volume><fpage>3103</fpage><lpage>3113</lpage><pub-id pub-id-type="pmid">9743377</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Yu</surname> <given-names>W</given-names></name><name><surname>He</surname> <given-names>T</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Caffrey</surname> <given-names>RE</given-names></name><name><surname>Dalmasso</surname> <given-names>EA</given-names></name><name><surname>Fu</surname> <given-names>S</given-names></name><name><surname>Pham</surname> <given-names>T</given-names></name><name><surname>Mei</surname> <given-names>J</given-names></name><name><surname>Ho</surname> <given-names>JJ</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Lopez</surname> <given-names>P</given-names></name><name><surname>Ho</surname> <given-names>DD</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor</article-title><source>Science</source><volume>298</volume><fpage>995</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1126/science.1076185</pub-id><pub-id pub-id-type="pmid">12351674</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhen</surname> <given-names>A</given-names></name><name><surname>Peterson</surname> <given-names>CW</given-names></name><name><surname>Carrillo</surname> <given-names>MA</given-names></name><name><surname>Reddy</surname> <given-names>SS</given-names></name><name><surname>Youn</surname> <given-names>CS</given-names></name><name><surname>Lam</surname> <given-names>BB</given-names></name><name><surname>Chang</surname> <given-names>NY</given-names></name><name><surname>Martin</surname> <given-names>HA</given-names></name><name><surname>Rick</surname> <given-names>JW</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Neel</surname> <given-names>NC</given-names></name><name><surname>Rezek</surname> <given-names>VK</given-names></name><name><surname>Kamata</surname> <given-names>M</given-names></name><name><surname>Chen</surname> <given-names>ISY</given-names></name><name><surname>Zack</surname> <given-names>JA</given-names></name><name><surname>Kiem</surname> <given-names>HP</given-names></name><name><surname>Kitchen</surname> <given-names>SG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS</article-title><source>PLOS Pathogens</source><volume>13</volume><elocation-id>e1006753</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006753</pub-id><pub-id pub-id-type="pmid">29284044</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.57646.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Davenport</surname><given-names>Miles P</given-names></name><role>Reviewing Editor</role><aff><institution>University of New South Wales</institution><country>Australia</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The search for an HIV 'cure' includes a number of approaches. These include eradication of the latent virus, as well as strategies to prevent viral replication. The known clinical examples of HIV 'cure' have occurred in patients that have received bone marrow transplants where the new donor marrow lacked the CCR5 gene that encodes an HIV co-receptor molecule. Thus, understanding how reduced CCR5 expression affects viral replication is an important question. In this study, the authors investigate viral control in SHIV infected macaques following autologous CCR5 gene-edited transplantation. To this end, they combine experimental data on SHIV-infected macaques with mathematical models describing viral and immune cell dynamics using a stepwise approach. This as a very innovative interdisciplinary study that provides important insights to inform potential future treatment regimens against HIV.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Thresholds for post-rebound SHIV control after CCR5 gene-edited autologous hematopoietic cell transplantation&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by Aleksandra Walczak as the Senior Editor, a Reviewing Editor, and two reviewers. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional work is required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is &quot;in revision at <italic>eLife</italic>&quot;. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p>Summary:</p><p>In this study, the authors investigate the requirements for viral control in SHIV infected macaques under CCR5 gene-edited HSPC transplantation treatment. To this end, they combine experimental data on SHIV-infected macaques with mathematical models describing viral and immune cell dynamics using a stepwise approach. The Materials and methods and Results are presented in a thorough way. The article utilizes a robust data set and also uses detailed mathematical models and extensive analyses to capture the relevant dynamics.</p><p>Essential revisions:</p><p>1) The authors perform model selection based on the AIC values to determine the appropriate mathematical model describing the observed dynamics. However, the reliability of the obtained AIC values also depends on the identifiability of the estimated model parameters. Can you say anything about the extent to which you are overfitting in these models? The number of parameters is quite large and you see some quite substantial correlations (Supplementary file 3).</p><p>2) Conditioning and CCR5-deleted autologous HSCT depletes existing infected cells and pre-existing immunity to SHIV and ultimately increases the proportion of infection-resistant cells after reconstitution. It's therefore not obvious that extensive conditioning is necessarily the best strategy, and you have shown this in Peterson et al., 2017 and Reeves et al., 2017. Could this be worth highlighting early on? It may help to increase the impact of the insights you derive from the modeling.</p><p>3) When modeling reconstitution in deltaCCR5 individuals – you assume that the CCR5- cells all behave like CCR5- cells in WT transplants. This doesn't seem like a valid assumption; a proportion of CCR5-/- cells will become activated (as they do in WT transplants) and so the CCR5-/- cell kinetics should be a mixture of the CCR5- and CCR5+ kinetics. The same parameters could be used in the two groups. How sensitive are your conclusions to this issue?</p><p>4) Subsection “A reduction in SHIV-specific immunity leads to higher viral rebound set points and CD4<sup>+</sup>CCR5+ T cell depletion following ATI in transplanted animals” and Figure 5E – this section needs more interpretation/discussion. It's surprising that the only difference in parameters between the control and treatment groups was the time to virus rebound; so presumably differences across groups derive from the steady state sizes of the different populations? Are latently infected cells depleted in the transplant groups? And it's puzzling that delayed rebound in transplant groups is taken to imply more depleted immunity. Shouldn't it imply less depletion? Also – elevated virus load after ATI only occurs in the WT transplant group, not both. Please clarify and expand this section.</p><p>5) Subsection “Post-ATI viral control requires a large HSPC dose containing a high fraction of CCR5-edited cells”: Are strategies 1 and 2 not in conflict? Or does more potent conditioning somehow not necessarily imply a greater reduction in anti-SHIV immunity?</p><p>In summary, the reviewers acknowledged the analysis of an important topic by a unique dataset. However, they identified some major aspects that addressed the parameter identifiability within the model estimates as well as identifying the role of conditioning and dynamics of CCR5- cells. Therefore, we would like to ask you to analyze/comment on parameter identifiability for individual model estimates and validate the robustness of parameter estimates and, hence, model selection. This will be subject to re-review to determine if these issues have been satisfactorily addressed.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;Thresholds for post-rebound SHIV control after CCR5 gene-edited autologous hematopoietic cell transplantation&quot; for further consideration by <italic>eLife</italic>. Your revised article has been evaluated by Aleksandra Walczak (Senior Editor) and a Reviewing Editor.</p><p>The manuscript has been improved but the reviewers have identified some remaining issues that need to be addressed before acceptance, as outlined below:</p><p>1) Figure 2—figure supplement 1, Panel B: The statistical comparison total vs. TN+TCM does not make sense. As I assume that Total=T<sub>N</sub>+T<sub>CM</sub>+T<sub>EM</sub>, &quot;Total&quot; does not contain additional information when there is already a comparison T<sub>N</sub>+T<sub>CM</sub> vs. T<sub>EM</sub>.</p><p>2) The manuscript contains a lot of typos and needs proofreading.</p><p>3) The Berlin and London patients are still not described.</p><p>4) The authors should provide all data and code used to perform the analyses.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.57646.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The authors perform model selection based on the AIC values to determine the appropriate mathematical model describing the observed dynamics. However, the reliability of the obtained AIC values also depends on the identifiability of the estimated model parameters. Can you say anything about the extent to which you are overfitting in these models? The number of parameters is quite large and you see some quite substantial correlations (Supplementary file 3).</p></disp-quote><p>We carefully took into account the following factors to reduce overfitting of the model and unidentifiability of the parameters as much as possible:</p><p>1) We divided the fits in two steps: (1) T cell reconstitution following TBI during virus suppression while on ART and (2) T cell and virus dynamics for the whole study period. The first step modeling fits to the isolated kinetics of T cells: expansion, overshoot and steady state. This method allows identification of parameters related to T cell reconstitution that do not correlate with parameters of virus dynamics. In the second step we fit to the same T cell subsets and to viral load data from acute infection and during ART interruption, fixing the parameters unrelated to virus infection and response from the first step. By using the two steps, parameters of the T cell dynamics related and unrelated to the virus dynamics are separately estimated.</p><p>2) The data during step (1) was frequently sampled for multiple T cell subsets allowing parameter identification related to each subset that were unrelated to virus dynamics (which is normally difficult when fitting models to viral loads only).</p><p>3) We transformed the model for step (1) as presented in the Materials and methods section after Equation 2 to ensure structural identifiability. Specifically, we combined several parameters, such as proliferation (r<sub>i</sub>), transition/differentiation and death rates (d<sub>i</sub>) into compound parameters and estimated the compound parameters. Whereas the individual rates were not identifiable, compound rates (capturing correlated behaviors) were.</p><p>4) The reparameterization shows that some different differentiation parameters (λ<sub>i</sub>) cannot be equal to zero, but others can be. For those that could take on a value of zero, we performed model selection to obtain a better fit and avoid overfitting.</p><p>5) We did careful model selection with reasonable models for step (1) (Figure 3—source data 2) using AIC to reject the most complex models and thus avoid overfitting (given the large amount of data compared to the number of parameters, AICc did not result in different outcomes). For each model we were careful in evaluating which parameters might not be practically identifiable and which ones correlated using the software Monolix:</p><p>a) For practical identifiability we used the relative standard error (standard error/population parameter value). Since the standard error is based on the diagonal of the inverse of the Fisher information matrix, it describes how much information each parameter gives to calculate the likelihood, and therefore gives information on how identifiable a parameter can be relative to the available data. We made sure the best model had small % relative standard error (%RSE&lt;=40) for most of the estimated parameters (Figure 3—source data 3). For some parameters, the standard deviation of the random effects were estimated to be close to zero but with very high %RSE values. We therefore assume those parameters have no random effects (standard deviation equal to zero), i.e. all animals have the same estimated individual value for that parameter.</p><p>b) For correlations among parameters Monolix also uses the inverse of the Fisher Information Matrix to give information about those correlations. For those with high correlation we fit the model again but explicitly including the statistical relationship between the parameters in the variance-covariance matrix Ω of the mixed-effects model (corr≠0 in Figure 3—source data 2 and Figure 5—source data 1 means that the correlations were explicitly part of Ω in the mixed-effect model—therefore they were estimated parameters also included in the AIC). We made sure that for the best model the estimated correlation was identifiable (i.e. low %RSE in Figure 3—source data 3 and Figure 5—source data 2). This means that when drawing individual parameter values from the distribution in the mixed-effect model, the estimated correlation was also taken into account.</p><p>6) Because of the possibility of lack of convergence by the SAEM fitting algorithm in Monolix, we repeated the fitting procedure for each model 10 times having randomly selected initial guesses for the parameters. From the 10 attempts we selected the case with the highest likelihood.</p><p>7) When fitting the model for step (2) we fixed all the estimated parameters in step one, including those with correlations. For practical identifiability and correlations of the parameters related with virus dynamics and response to the virus we followed the same procedure as in item 5 (all summarized in the “statistical assumptions” in Figure 5—source data 1. See also the %RSE for best model estimates in Figure 5—source data 2 – most of them with %RSE &lt;=40%).</p><p>8) For both steps, we fixed some parameters based on estimation from previous studies.</p><p>We recognized the possibility of model overfitting and unidentifiability of parameters, but we believe that the careful steps we took reduced those two problems significantly.</p><disp-quote content-type="editor-comment"><p>2) Conditioning and CCR5-deleted autologous HSCT depletes existing infected cells and pre-existing immunity to SHIV and ultimately increases the proportion of infection-resistant cells after reconstitution. It's therefore not obvious that extensive conditioning is necessarily the best strategy, and you have shown this in Peterson et al., 2017 and Reeves et al., 2017. Could this be worth highlighting early on? It may help to increase the impact of the insights you derive from the modeling.</p></disp-quote><p>We have included a sentence in the Introduction explaining that extensive conditioning is a necessary condition (despite the loss of pre-existing immunity) to reduce the number of endogenous HSCs so that transplanted CCR5-deleted HSCs can outcompete with them.</p><p>We also added a sentence in the Discussion saying that in the absence of conditioning the number of endogenous HSPCs will remain too high. In this case, the amount that would have to be taken from the animals for ex-vivo CCR5 deletion and transplantation for SHIV remission would be unrealistic, and their engraftment potential would be low.</p><disp-quote content-type="editor-comment"><p>3) When modeling reconstitution in deltaCCR5 individuals – you assume that the CCR5- cells all behave like CCR5- cells in WT transplants. This doesn't seem like a valid assumption; a proportion of CCR5-/- cells will become activated (as they do in WT transplants) and so the CCR5-/- cell kinetics should be a mixture of the CCR5- and CCR5+ kinetics. The same parameters could be used in the two groups. How sensitive are your conclusions to this issue?</p></disp-quote><p>We agree with the reviewers that the CCR5-/- cell kinetics could be a mixture of the CCR5- and CCR5+ kinetics. We added models that include this feature (12 new mechanistic models for T cell reconstitution part, and 4 new mechanistic ones for the section including viral dynamics) and found that the results/conclusions of the paper are not sensitive to this change:</p><p>1) We modified Equation 2 and Figure 3A to account for the possibility that CD4<sup>+</sup>CCR5-disrupted cells can have kinetics of CCR5- and CCR5+ cells, N<sub>p1</sub> and N<sub>p2</sub> compartments in the model, respectively.</p><p>a) We therefore added 12 more models including N<sub>p2</sub> (models 13-24 in Figure 3—source data 2) with the same statistical assumptions for the models without N<sub>p2</sub>.</p><p>b) We fit the new 12 models to the T cell reconstitution data and found that the best model with compartment N<sub>p2</sub> has almost the same AIC (Figure 3—source data 2 -models 11 and 23) and parameter estimates (Figure 3—source data 3) that the best model without N<sub>p2</sub>.</p><p>c) From this part we deduced that:</p><p>i) T cell reconstitution data could not be used to distinguish if CD4<sup>+</sup>CCR5-disrupted cells have a mixture of the CCR5- and CCR5+ kinetics.</p><p>ii) But regardless, the model with mixture of the CCR5- and CCR5+ kinetics didn’t differ at all from a model without that mixture.</p><p>2) When fitting viral load, we also tried to fit the model using the compartment N<sub>p2</sub> (Models 5-8 in Supplementary file 5)</p><p>a) From this step we found that the model with mixture of the CCR5- and CCR5+ for disrupted cells had a significantly lower AIC (Figure 5—source data 1).</p><p>b) However model fits and comparisons between parameters and viral load steady state did not change (Figure 5, Figure 5—figure supplement 1, Figure 5—figure supplement 2, Figure 5—figure supplement 3, Figure 5—source data 2 and Figure 5—source data 3).</p><p>c) When using the best model with corresponding parameter estimates the model projections using different fp, Dose and Pr did not change either (Figure 6A-B). Minimum fp and Dose:Pr were very close to values obtained before: 76%-94%, and D:Pr&gt;5, respectively (Figure 6C). Also, the relation of immune response (R<sub>T</sub>) and minimum f<sub>p</sub> was the same (Figure 6D).</p><p>d) Finally, when using the model for projections of viral control for different times of ATI, we obtain the same decrease pattern of time to control.</p><p>We edited the text to include these analyses.</p><disp-quote content-type="editor-comment"><p>4) Subsection “A reduction in SHIV-specific immunity leads to higher viral rebound set points and CD4<sup>+</sup>CCR5+ T cell depletion following ATI in transplanted animals” and Figure 5E – this section needs more interpretation/discussion. It's surprising that the only difference in parameters between the control and treatment groups was the time to virus rebound; so presumably differences across groups derive from the steady state sizes of the different populations? Are latently infected cells depleted in the transplant groups? And it's puzzling that delayed rebound in transplant groups is taken to imply more depleted immunity. Shouldn't it imply less depletion? Also – elevated virus load after ATI only occurs in the WT transplant group, not both. Please clarify and expand this section.</p></disp-quote><p>Since the best model we obtained allowed distinct SHIV-specific CD8s parameter values for the ATI and pre-ART stages, we re-analyzed the data and model results using a different approach to address what drives different kinetics between the control and transplant groups.</p><p>1) We looked first at how viral load burden differed during ATI compared to pre-ART using three summary statistics: median, nadir and final viral loads from viral peak onwards for each stage (ATI vs pre-ART). Figure 4B-D now presents that result.</p><p>2) We compared each of these summary statistics per group and found that in the three summary statistics viral burden during ATI is maintained or slightly decreased for the control group, increased for the WT-transplant group (no CCR5-edition), and is increased for the CCR5-edited group but not nearly to the degree seen in the WT group.</p><p>3) Then, we compared how the model predicts that SHIV-specific immunity changed during ATI with respect to pre-ART using the parameters directly related to SHIV-specific CD8<sup>+</sup> T cells (since we can only measure this with the model and not in the data). We found that SHIV-immunity change at ATI compared to pre-ART was correlated to the change in viral burden between ATI and pre-ART (median and nadir viral load during ATI:pre-ART). These results are now presented in Figure 5C-D. SHIV-immunity during ATI slightly increased for the control group (ratio over 1), decreased for the WT-transplant group, and was recovered for the CCR5-edited group</p><p>We have clarified and expanded these analyzes in the viral and T cell dynamics modeling result section.</p><p>Regarding if latently infected cells are depleted in the transplant groups, Peterson et al., 2017 and Reeves et al., 2017 support that conclusion. However, answering this question from a mathematical modeling perspective was beyond the scope of this study. For that reason, we did not explicitly have a model for the SHIV-latently infected cell compartment, or how they could have been depleted during conditioning (as we did for all other cell compartments). We only added a constant parameter <inline-formula><mml:math id="inf268"><mml:mrow><mml:mi>ξ</mml:mi><mml:mover><mml:mi>L</mml:mi><mml:mo accent="true">¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> to account for their reactivation. In the model, time to rebound was only related to latent cell reactivation <inline-formula><mml:math id="inf269"><mml:mrow><mml:mo form="prefix" stretchy="true">(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mtext mathvariant="normal">sa</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>ξ</mml:mi><mml:mover><mml:mi>L</mml:mi><mml:mo accent="true">¯</mml:mo></mml:mover></mml:mrow></mml:mfrac><mml:mo form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:math></inline-formula>, but viral load kinetics after peak was related to SHIV-immunity as described above. It is possible that delayed rebound is a response to some depletion of latent cells during conditioning, and therefore, less reactivated latent cells. In that sense there is a connection of delayed rebound and depletion of SHIV-immunity during conditioning. However, exploring this relationship was beyond the scope of this study. Therefore, we have taken out the figure presenting how time to rebound was different among groups and its discussion from the manuscript to avoid confusion to the message we are presenting. Also, this result has already been presented in Peterson et al., 2018.</p><disp-quote content-type="editor-comment"><p>5) Subsection “Post-ATI viral control requires a large HSPC dose containing a high fraction of CCR5-edited cells”: Are strategies 1 and 2 not in conflict? Or does more potent conditioning somehow not necessarily imply a greater reduction in anti-SHIV immunity?</p></disp-quote><p>We believe they are not in conflict in the sense that we don’t mean in strategy 1 to reduce conditioning, but to find ways to augment anti-SHIV immunity despite conditioning. Several examples could include anti-SHIV CAR T cells and/or immunotherapies based on broadly neutralizing antibodies to specifically target the persistent viral reservoir but not virus-specific immune cells, and/or conditioning strategies that are targeted more specifically to HSPCs, without impacting differentiated immune subsets. In that sense we have changed the wording of strategy 1 as “augment anti-SHIV immunity despite conditioning”.</p><disp-quote content-type="editor-comment"><p>In summary, the reviewers acknowledged the analysis of an important topic by a unique dataset. However, they identified some major aspects that addressed the parameter identifiability within the model estimates as well as identifying the role of conditioning and dynamics of CCR5- cells. Therefore, we would like to ask you to analyze/comment on parameter identifiability for individual model estimates and validate the robustness of parameter estimates and, hence, model selection. This will be subject to re-review to determine if these issues have been satisfactorily addressed.</p></disp-quote><p>We appreciate the reviewer’s comments and acknowledgements and believe we have addressed to the best of our abilities the major aspects regarding parameter identifiability/model selection, role of conditioning and dynamics of CCR5- cells.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>The manuscript has been improved but the reviewers have identified some remaining issues that need to be addressed before acceptance, as outlined below:</p><p>1) Figure 2—figure supplement 1, Panel B: The statistical comparison total vs. TN+TCM does not make sense. As I assume that Total=T<sub>N</sub>+T<sub>CM</sub>+T<sub>EM</sub>, &quot;Total&quot; does not contain additional information when there is already a comparison T<sub>N</sub>+T<sub>CM</sub> vs. T<sub>EM</sub>.</p></disp-quote><p>We have changed Figure 2—figure supplement 1, Panel B: taking out the statistical comparison for total vs. TN+TCM</p><disp-quote content-type="editor-comment"><p>2) The manuscript contains a lot of typos and needs proofreading.</p></disp-quote><p>We have proofread the manuscript and took care of the typos we found.</p><disp-quote content-type="editor-comment"><p>3) The Berlin and London patients are still not described.</p></disp-quote><p>We have included a description of the Berlin and London patients in the Introduction.</p><disp-quote content-type="editor-comment"><p>4) The authors should provide all data and code used to perform the analyses.</p></disp-quote><p>Besides of the code already submitted we have provided the code for analyses in Figure 2, Figure 3, Figure 4, Figure 5 and Figure 6.</p></body></sub-article></article>